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ABSTRACT

Rodriguez-Rodriguez, Yelitza A., Ph.D., University of South Alabama, May 2022. The
role of nuclear focal adhesion kinase (FAK) in tumor and the tumor microenvironment.
Chair of Committee: Dr. Steve Lim, Ph.D.
Focal adhesion kinase (FAK) is a ubiquitous expressed protein tyrosine kinase. In
growing cells, FAK localizes to the plasma membrane where it interacts with several
components of the focal adhesion complex and coordinates integrin signaling. Early
studies using genetic mouse models revealed that deletion or catalytic inactivation of
FAK resulted in early embryonic lethality with vascular, cell proliferation, and cell
survival defects. As a result, FAK was coined as a vital mediator of cell migration,
proliferation, and cell survival and multiple small molecule FAK inhibitors (FAK-I) had
been designed to inactivate FAK catalytic functions in multiple pathologies, particularly
in cancer. FAK-I had demonstrated efficacy in alleviating tumor growth and metastasis,
and some are currently in clinical developmental phases. Inactive FAK is nuclear
localized and still retains important scaffold functions that we scarcely know about. More
importantly, little is known about the impact of inactive nuclear-localized FAK in solid
tumors or in the tumor microenvironment (TME, the immediate surrounding of tumors
cells). In this dissertation, I sought to dissect the role of nuclear FAK localization in
cancer progression by focusing in two cell types of the TME: tumor (chapter II) and
endothelial cells (chapter III) FAK-I prompted FAK nuclear localization in B16F10
melanoma cells. Nuclear FAK was able to bind and ubiquitinate DNA methyltransferase
xix

3A (DNMT3A), thus reducing DNMT3A protein stability. Loss of DNMT3A reduced
global DNA methylation which increased the expression of the tumor suppressor gene,
suppressor of cytokine signaling 3 (SOCS3). Tetracycline inducible (Tet-on) SOCS3
expression reduced B16F10 melanoma proliferation and viability. Stable knockdown of
DNMT3A, increased SOCS3 expression. FAK-I also blocked B16F10 melanoma ear
tumor growth, reduced DNMT3A expression and increased SOCS3 in vivo.
Further, genetic, and pharmacological inhibition of FAK blocked vascular
endothelial growth factor (VEGF)/ fibroblast growth factor (FGF)-induced Matrigel plug
angiogenesis in vivo. FAK-I reduced HB-EGF protein and mRNA expression in various
mouse, human EC lines and human infantile hemangioma cell lines, resulting in reduced
EC proliferation. FAK-I also reduced HB-EGF mRNA expression in vivo anagenesis
model. Mechanistically, FAK-I reduced nuclear localization, tyrosine phosphorylation
and protein stability of the transcriptional coactivator, yes associated protein 1 (YAP)
which reduced HB-EGF expression. Taken together, the information gathered in this
dissertation suggests that nuclear-localized FAK negatively regulates cancer progression
by increasing the expression of tumor suppressor genes in tumor cells and blocking the
expression of angiogenic factors in endothelial cells.

xx

CHAPTER I:
BACKGROUND

Cancer is a major cause of death in the United States of America (USA), more
than a million cases of cancer are diagnosed annually in the USA, and more than 500,000
Americans die of cancer each year [1]. Cancer occurs when a single cell divides and
accumulates genomic mutation that confers the ability to grow uncontrolled giving rise to
a tumor. Tumors can be categorized into two types: benign or malignant tumors. Benign
tumors only grow to a certain size and lack the ability to invade surrounding tissue.
However, malignant tumors can invade surrounding tissue and spread to other distant
sites of the original tumor, which is known as metastasis [2]. The sum of steps that grant
the ability of tumors to invade and travel distant sites of the body is known as cancer
progression. Cancer progression is a complex multistep phenomenon initiated and
maintained by a supportive tumor microenvironment (TME). The TME is the immediate
niche surrounding tumors and is composed of blood and lymphatic vessels, immune cells
(T and B cells, natural killer cells, macrophages), stromal cells (fibroblasts, mesenchymal
cells, pericytes, some adipocytes), secreted factors and extracellular matrix (reviewed in
[3,4]). The tumor and TME exhibit a remarkable amount of crosstalk that influences
cancer progression, metastasis, survival, and tumor immune landscape (reviewed in [57]). In this dissertation, I sought to better understand key signaling molecules that
modulates the interaction between the cells in the TME, particularly, tumor cells and
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tumor-associated endothelial cells (ECs), to find druggable targets that could help to
eradicate tumor growth and to interrupt tumor-associated angiogenesis.

Structure and function of focal adhesion kinase (FAK)
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that is
primarily regulated by integrin signaling. Additionally, various transmembrane receptors
including G-protein coupled, cytokine and growth factor receptors can coordinate to
transmit extracellular signals through FAK [8-10]. FAK structure can be divided into
three main domains: an N-terminal band 4.1, ezrin, radixin, moesin homology (FERM), a
central kinase, and a C-terminal focal adhesion targeting (FAT) domain (Figure 1). When
FAK is activated upon integrins or growth factor receptor signaling, tyrosine (Y) 397 site
is autophosphorylated. Since FAK is a key mediator of integrin signaling through its
association with focal adhesion proteins, such as talin and paxillin, it was thought that
FAK localization might be limited to the cytosol and plasma membrane. This idea was
later challenged by the identification of a functional nuclear localization sequence (NLS)
within FAK FERM domain [11], which has since expanded the scope of FAK signaling
to the regulation of nuclear proteins and gene expression. Although the role of nuclear
FAK is not fully understood, several studies have shown that nuclear FAK may act as a
key player in regulating gene expression by interacting with numerous transcription
factors (NANOG, TAF9, MEF2, Runx1, RNA polymerase II), E3 ligases (mdm-2, CHIP)
and epigenetic regulators (HDAC1, MBD2, Sin3a) (Figure 1) [11-16]. The first nuclear
FAK studies demonstrated that the FERM domain acts as a scaffold to promote
ubiquitination and proteasomal degradation of nuclear factors (e.g., p53 and GATA4) by
2

forming a complex with E3 ligases (e.g., mdm-2 and CHIP) (Figure 1) [11,12,17].In
growing cells, FAK constantly shuttles between the cytoplasm and nucleus through its
NLS and nuclear export sequence (NES) within its kinase domain (Figure 1) [11,18].
However, this localization drastically opposes our latest finding in which we
demonstrated that FAK predominantly localized to the nucleus in vascular smooth
muscle cells (VSMC) of healthy arteries [12], suggesting that FAK localization may
differ in vivo and in vitro. FAK controls fundamental cellular processes – cell adhesion,
migration, proliferation and survival [19] – and promotes important malignant features of
cancer progression – cancer stemness, epithelial to mesenchymal transition (EMT), tumor
angiogenesis, chemotherapeutic resistance and fibrotic stroma (reviewed in [20,21]).
FAK expression is frequently upregulated in different types of cancer, and most studies
have focused on either reducing FAK expression and/or activity to inhibit growth and
metastatic capacity of tumors. However, more recent reports suggest that FAK may also
contribute to cancer progression by regulating multiple factors within the TME.

FAK signaling in the tumor microenvironment (TME)
Although we tend to think that tumor cells exist in isolation, tumors develop in complex
and dynamic microenvironments that dictate their growth, invasion, and metastatic
capacity [22]. In this space, tumor cells and their neighboring microenvironments are in
frequent communication. The interaction of cancer cells with their microenvironment
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Figure 1. Structural organization of the family of focal adhesion kinase (FAK).
FAK comprises three main domains: the FERM (4.1, ezrin, radixin, moesin), central
kinase and FAT (focal adhesion targeting) domains. FAK contains both a nuclear
localization sequence (NLS) and a nuclear export sequence (NES), which are in the
FERM and the kinase domains, respectively. FAK-interacting proteins, including
transcription factors, epigenetic regulators, and E3 ligases, are shown. While TAF9,
Runx1, RNA pol II, Sin3A, and HDAC1 also interact with FAK, the interacting FAK
domain for each remains uncharacterized. Y397: FAK autophosphorylation site. a.a.:
amino acids. PRR: proline-rich region. N: N-terminus. C: C-terminus.
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is dynamic and bidirectional and includes cell-cell contacts, or cell-free contacts
(involving ECM) and the mediators that enable these contacts. Mediators are secreted
soluble molecules/factors/vesicles that are responsible for the horizontal transfer of
genetic information between cellular/non-cellular communicating cells. Current
approaches to eradicate tumor growth look at druggable targets to intervene
communication within the TME. Recent studies have demonstrated the role of FAK in
promoting TME remodeling including angiogenesis, immune evasion, and ECM
production which exacerbate tumor progression (Figure 2). Targeting FAK in both, the
tumor and the TME, could prove beneficial in reducing tumor-TME interactions and
reducing tumor progression.

The role of FAK in tumor cells
FAK functions can be broadly separated into two categories: cytosolic and
nuclear. Cytosolic FAK functions include signaling cascades of transmembrane
receptors, which enhances focal adhesion turnover, cell migration, and gene expression in
response to extracellular signals. FAK’s cytosolic signaling functions have been
extensively studied [20,23]. Below are some of the most notorious roles of FAK in tumor
cells.
FAK gene amplification
FAK is encoded by PTK2 gene; located at chromosome band 8q24.3. FAK is
overexpressed in various cancers, including ovarian, cervical, kidney, lung, pancreatic,

5

Figure 2. Role of FAK in the tumor and the tumor microenvironment (TME).
The TME comprises a heterogeneous population of cells and acellular components.
The orchestration of signaling pathways and communication between cell populations
within the TME significantly dictates the fate of tumor growth and development. FAK
has been shown to play an important role in the regulation of tumor and TME functions
to provide a favorable and protumorigenic niche.
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brain, colon, breast, and skin cancer [24] (Figure 3). In addition, studies have confirmed a
correlation between FAK overexpression levels and poorer clinical prognosis in several
types of human tumors [25]. One important mechanism of FAK overexpression is gene
amplification, and increased FAK transcription [26-29]. Although the correlations
between FAK gene amplification and tumor progression in certain other human tumors
have been inconsistent, FAK gene amplification was found to be a poor prognostic factor
as well as an important indicator in gastric cancer [30], high-grade serous ovarian cancer
[31] and in invasive breast cancer [25]. In contrast, overexpression of FAK in head and
neck squamous cell carcinoma is independent of FAK gene amplification [32] there are
still significant correlations between some invasive cancers and high FAK mRNA levels.
Cancer initiation and cancer cell survival
FAK expression was first shown to be an important regulator of the initiation and
survival of cancer cells by its ability to prevent cell apoptosis in Madin-Darby canine
kidney (MDCK) cells [33]. Similarly, genetic FAK deletion in skin keratinocytes has
been shown to suppress dimethyl benzanthracene (DMBA)-induced skin cancer
formation and to induce cell apoptosis in vitro and in vivo [34]. Also, mammary tissuespecific FAK knockout with p53 deletion has been shown to reduce mammary tumor
formation [35]. FAK siRNA-mediated knockdown or overexpressing the FAK C-terminal
domain (dominant negative inhibitor of full length FAK) can decrease cell proliferation
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Figure 3. Copy number variations of FAK gene, PTK2, in several cancers.
FAK gene, PTK2, is located at chromosome band 8q24.3, amplification of FAK gene is common in many
tumors. Here are shown copy number variations of PTK2, in several cancers cohorts in the Cancer Genome
Atlas (TCGA) as a percentage of cases that display aberrant copies to PTK2. The impact of FAK gene
amplification in patient prognosis is not consistent across cohorts available in the TCGA, however, in certain
cancers such as stomach adenocarcinoma, ovarian cancer and invasive breast cancer FAK gene amplification is
associated with poor prognosis.

and tumor growth in breast cancer cells [24]. Taken together, these studies suggest that
FAK is critical in cancer cell survival.
Regulation of cancer stem cells (CSC)
Some tumor cells have the ability to self-renew and to differentiate into
undifferentiated tumorigenic cells, a population of cells is known as cancer stem cells
(CSCs) [36]. Although CSCs were first isolated from leukemia [37], now we know about
several solid tumors, including brain, breast, prostate and pancreas cancers [38-42] that
have such populations of cells. FAK deletion in a murine breast cancer model led to a
decrease in the number of mammary CSCs and a decrease in their self-renewal potential;
this ultimately inhibited tumor progression [43]. There is crescent evidence that indicates
that FAK is involved in the expression of several stem cell factors. This is because FAK
maintains the expression of critical transcription factors Slug (Snail family zinc finger 2)
and Sox9, which were identified as important factors in maintaining mammary CSCs
[44]. Other regulators of cancer cells stemness such as NANOG have been shown to bind
to FAK promoter and increase the level of FAK expression and activity in HEK 293,
SW480, and SW620 cancer cells [45]. These studies indicate that FAK expression may
have an important role in the control of CSC function and activity.
Nuclear FAK functions
On the other hand, the discovery of nuclear FAK regulation of gene expression
has added another layer of complexity to FAK signaling. Nuclear FAK regulation of
tumor suppressor p53 stability was the first study to demonstrate the importance of
nuclear FAK function in cell survival and gene expression [11]. Further characterization
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of FAK nuclear localization demonstrated a series of favorable conditions that promote
FAK nuclear localization includes loss of cell attachment and apoptosis inducers [11].
These conditions are commonly associated with loss of FAK catalytic activity, and
indeed, FAK inhibition by small-molecule FAK inhibitors or genetic FAK kinase-dead
(KD) mutation significantly promotes FAK nuclear localization [17]. The FAK-KD
knockin model further supported a kinase-independent scaffold function of nuclear FAK
in mice and mouse embryonic fibroblasts (MEFs) to regulate proinflammatory signaling.
In MEFs, nuclear FAK enhances the transcription factor, GATA4 degradation and blocks
the expression of tumor necrosis factor-⍺ (TNF-⍺) stimulated vascular cell adhesion
molecule-1 (VCAM-1) [17]. This study has implicated that nuclear FAK may function as
an anti-inflammatory signal.
New molecular mechanisms of nuclear FAK function in tumor progression have
been further investigated using skin squamous carcinoma cells (SCCs), triple-negative
breast cancer cells (TNBCs), and human melanomas. Interestingly, FAK-/- SCCs reexpressing wild-type FAK showed abundant nuclear FAK in vitro in contrast to the lack
of nuclear FAK in normal keratinocytes [46]. In SCCs, nuclear FAK promotes the
expression of different chemokines including CCL5 and TGFβ2 [46], which causes
immunosuppression in TME. Interestingly, SCCs expressing either FAK KD (inactive
but nuclear-localized) or FAK-NLS mutant (active but cytosol restricted) failed to
promote CCL5 expression, suggesting that nuclear FAK may exhibit some catalytic
activity required for chemokine transcription. This upregulation in gene expression was
potentially through FAK interaction with TAF9, which is a part of the transcription factor
II D complex that makes up the RNA polymerase II preinitiation complex. However, the
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exact mechanism through which nuclear FAK regulates TAF9 to promote gene
expression is not known. In another study with SCCs, nuclear FAK was shown to
downregulate the expression of the tumor suppressor, insulin-like growth factor binding
protein 3 (IGFBP3), by promoting the interaction between the transcription factor
RUNX1 and the transcriptional suppressor Sin3a [15]. Interestingly, suppression of
IGFBP3 transcription was independent of FAK catalytic activity and was solely due to a
kinase-independent role of nuclear FAK [15]. The finding is in contrast with previous
observations where active nuclear FAK-mediated SCC immunosuppression [46].
Although it was not clearly demonstrated that nuclear FAK is active in SCCs, it will be
intriguing to find any target proteins phosphorylated by nuclear FAK.
Several studies have indicated that FAK and NANOG, a transcription factor
critical for the maintenance of stemness, regulate each other to promote an aggressive
tumor phenotype. In colon cancer cells, NANOG was shown to bind the FAK promoter
and increase FAK expression [45]. NANOG was then found to bind to FAK and be
phosphorylated by FAK, and FAK-NANOG interaction promoted cancer cell
pluripotency and invasive capacity. The FAK FERM domain is responsible for FAK
association with NANOG, and mutation of Y35F and Y174F (tyrosine to phenylalanine)
of NANOG disrupted FAK-NANOG association and reduced cancer cell invasiveness
[45]. FAK and NANOG were shown to colocalize to the nucleus and perinuclear region
but Y35F and Y174F NANOG mutants showed decreased nuclear localization,
suggesting that FAK phosphorylation and interaction may regulate NANOG nuclear
translocation and transcriptional activity in colon cancer cells. FAK and NANOG were
further shown to interact within the CSC population of TNBC cells through their
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interaction with the cell to cell adhesion molecule, connexin 26 (Cx26) [13]. The
interaction between FAK and NANOG in the nucleus and cytoplasm was unique to
TNBC CSCs and did not occur in non-CSCs. In normal epithelial or luminal breast
cancer cells, FAK and NANOG did not bind each other but did associate with Cx26. In
TNBC CSCs, Cx26 seems to promote NANOG protein stability and increase FAK
activity. While FAK is known to phosphorylate NANOG in colon cancer cells, FAK
activity was not required for the formation of the Cx26/FAK/NANOG complex in TNBC
CSCs [13]. Using human breast cancer data sets, this study further found that TNBC
patients with higher levels of Cx26/FAK/NANOG had decreased relapse-free survival
compared to those with lower expression. While these studies suggest that nuclear FAK
within cancer cells helps promote an aggressive phenotype, it is still not known why or
how nuclear FAK is increased within some types of cancers.
In a knock-in mouse model, homozygous Y397F (tyrosine to phenylalanine
mutation) FAK mice were embryonic lethal at embryonic day 9.5 and showed a similar
phenotype to fibronectin-deficient embryos [47]. Mass spec analysis of proteins that bind
the Y397 containing peptide in the FERM-kinase linker found that only myosin-1E
(Myo1E) bound both the phosphorylated and non-phosphorylated Y397 containing
peptide. In melanoma cells, Myo1E binding to FAK increases FAK activity, and Myo1E
also promotes FAK nuclear localization. Nuclear FAK promoted the expression of
several extracellular matrix (ECM) proteins, such as osteopontin and fibronectin, which
drive melanoma proliferation [47]. They also demonstrated that pharmacological FAK
inhibition reduced pY397 FAK and reduced nuclear FAK, showing that FAK activity in
human melanoma may be important in promoting FAK nuclear localization. However,
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the study did not reveal the mechanism of how FAK activity contributes to nuclear
localization of FAK or ECM gene expression.
More recent studies have focused on investigating the localization of both total
and active FAK within the nucleus of various cancer specimens. Using large numbers of
human tumor samples, they found nuclear staining of active pY397 FAK within several
types of cancers including lung, colorectal, and breast cancer [48-50]. Interestingly, the
colorectal and breast cancer studies showed that elevated nuclear pY397 FAK was
associated with a poor prognosis and decreased patient survival [49,50]. Patient survival
from both small-cell lung cancer and non-small-cell lung cancer did not correlate with
increased levels of nuclear pY397 FAK [48], suggesting that nuclear pY397 FAK may
play different roles in the progression and aggressiveness of different tumor types.
Ovarian cancer also showed increased pY397 FAK in tumor cells compared to stromal
cells and was widely distributed in both the cytosol and nucleus [31]; however, this study
did not investigate the role of nuclear FAK in ovarian cancer or any association with
patient survival. Although these immunohistochemical analyses of human cancers have
provided new insights into the prevalence and potential importance of active nuclear
FAK within tumor cells, more comprehensive analyses of nuclear FAK localization and
activity in various types of tumors are needed to understand FAK’s role in the nucleus of
cancer cells.
The role of FAK in immune cells infiltration to TME
Immunotherapy using the host immune system to target cancer cells has become
increasingly popular over the last several years. Tumors secrete various cytokines,
chemokines, and extracellular matrix proteins that promote an immunosuppressive
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environment, thus promoting tumor cell survival [51]. A recent study showed that
squamous cell carcinoma (SCC) exhibits an abundant level of nuclear FAK. Loss of FAK
expression in SCCs promoted tumor regression and that re-expression of FAK wild-type,
but not kinase-dead (KD) FAK, promoted tumor progression [46]. This study found that
nuclear FAK increased expression of CCL1, CCL5, CCL7, CXCL10, and TGFβ2,
chemokines and cytokines responsible for recruitment and expansion of CD4+ regulatory
T cells (Tregs) [46]. The recruited Tregs promoted tumor survival by exhausting the
CD8+ cytotoxic T cell population responsible for tumor cell clearance [52].
Pharmacological FAK inhibition in mice bearing SCC tumors also led to a decrease in
Treg cell recruitment and an increase in cytotoxic CD8+ T cells [46], demonstrating that
pharmacological FAK inhibitors can promote active immune surveillance in the TME to
prevent tumor progression. A follow-up study showed that nuclear FAK enhanced gene
expression of interleukin (IL)-33, an IL-1 family cytokine that can be secreted or stays
within the nucleus. Nuclear FAK interacted with IL-33 to increase transcription of the
soluble ST2 receptor (sST2), for which IL-33 is a ligand [14]. Increased sST2 then
blocked recruitment and activation of CD8+ cytotoxic T cells by acting as a sink for
extracellular IL-33 [14]. The FAK-IL-33 complex was also shown to interact with
chromatin modifiers WDR82 and BRD4, suggesting that nuclear FAK may help promote
open chromatin structure to increase transcription of chemokine genes in SCCs. Although
the study revealed that both nuclear FAK and its activity may be important for
transcription for different chemokines potentially through FAK’s association with the
WDR82, BRD4, and the TAF9 transcription factor, the molecular mechanism of how
FAK activity in the nucleus contributes to chemokine transcription is not clear.
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T cells require co-stimulatory receptor activation to become fully active and to
promote tumor cell clearance. A recent study demonstrated that cancer cells expressing
the T cell co-stimulatory ligand, CD80, were more sensitive to pharmacological FAK
inhibition and clearance by CD8+ cytotoxic T cells [53]. CD80 can associate with either
CD28, promoting cytotoxic T cell activation and tumor clearance, or associate with
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) to block cytotoxic T cell
activation and promote tumor survival [54]. Although the mechanistic signaling pathways
remain elusive, FAK inhibition increased the CD28+ T cell population within the TME.
CD80 expressing tumors were susceptible to FAK inhibitor-induced tumor regression
through decreased recruitment of T cells expressing CTLA4, preventing T cell
desensitization, activating and boosting T cell cytotoxic expansion and functions [53].
FAK inhibition was also able to promote clearance of CD80-deficient tumors when
combined with antibody agonists to T cell co-stimulatory receptors such as OX-40 and 41BB [53]. These studies highlight the potential benefits from the combined use of FAK
inhibitors and immunotherapy to alter the T cell population of the TME to promote tumor
regression.
Immune cells play a key role in both tumor survival and clearance (reviewed in
[55]). The recruitment of various types of immune cells, such as Treg, CD4+ T cells,
CD8+ T cells, tumor-associated macrophages, and natural killer cells, play distinct roles
in either promoting tumor cell survival or clearance. A recent study has illustrated the
importance of FAK expression within myeloid cells of the TME. In an MMTV-polyoma
middle T murine model of breast cancer, FAK was knocked out in mononuclear
phagocytic cells using LysM-Cre [56]. Interestingly, loss of FAK expression in myeloid
16

cell lineages delayed the formation of adenomas and carcinomas compared to the wild
type of control. However, in established tumors, FAK knockout myeloid cells accelerated
tumor growth and volume than wild type [56]. This increase in tumor size was associated
with decreased natural killer cells within the tumor, suggesting that FAK expression in
myeloid cells is important for either natural killer cell recruitment and/or survival within
the TME [56]. While this study used a FAK knockout model, more studies are needed to
investigate the role of FAK catalytic activity or nuclear role of FAK in myeloid cells on
recruitment of other immune cells to the TME.
The role of FAK in tumor-associated endothelial cells (ECs)
It is known that FAK expression is upregulated in vascular cells surrounding solid
tumors [57,58]. Numerous studies have investigated the role of FAK within endothelial
cells (ECs) in tumor survival, angiogenesis, and metastasis. EC-specific deletion of FAK,
just prior to tumor implantation, demonstrated that FAK expression is required for
vascular endothelial growth factor (VEGF)-induced angiogenesis and subsequent tumor
growth [59]. The importance of FAK catalytic activity in ECs during tumor formation
was further investigated by using an autophosphorylation mutant, FAK Y397F (tyrosine
to phenylalanine), which lacks catalytic activity or a FAK Y861F mutant which disrupts
FAK association with downstream target proteins. The mutation of either one of these
tyrosine residues reduced the initiation of tumor angiogenesis, suggesting that FAK
activity in ECs is important for tumor growth [60]. However, FAK Y861F mutant
showed increased angiogenesis in late-stage tumors. The differences in these two genetic
mice were that while FAK Y397F ECs showed decreased VEGF receptor 2 (VEGFR2)
expression and b1 integrin activation, FAK Y861F ECs showed enhanced b1 integrin
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activation through angiopoietin 2 signaling [60]. Interestingly, another study revealed that
FAK nuclear localization and kinase activity were critical for VEGFR2 transcription and
that FAK bound the VEGFR2 promoter following VEGF treatment in mouse ECs [61].
This study sheds light on the importance of investigating the role of nuclear FAK in ECs
during tumor angiogenesis.
Increased vascular permeability promotes tumor metastasis by making it easier for
cancer cells to enter and exit the bloodstream. FAK expression has been demonstrated to
promote metastasis through increased vascular permeability and disorganized vessel
structure [62]. Loss of FAK expression within ECs increased both cell-cell junctions and
astrocyte-endothelium interactions which led to decreased permeability within glioma
[62]. More importantly, it was shown that FAK activity in ECs promotes tumor cell
metastasis by promoting vascular permeability through VEGF [63]. Mechanistically,
VEGF promotes FAK activation, rapid FAK localization to cell-cell junctions, binding of
FAK FERM domain to vascular endothelial cadherin (VE-cadherin), and the direct
phosphorylation of b-catenin at Y142 facilitating EC junction breakdown by dissociating
VE-cadherin-b-catenin complex. By using an EC-specific FAK kinase-dead (KD) model,
a study found that FAK catalytic activity within ECs was important for disrupting the EC
barrier not only by phosphorylating b-catenin at Y142 but also phosphorylating Y658 on
VE-cadherin [64]. While this study focused on loss of FAK catalytic activity within the
cytoplasm, FAK KD has been shown to be enriched in the nucleus and the role of nuclear
FAK in the regulation of vascular permeability needs to be investigated further [12].
Metastasis is a complex process, which involves tumor cell intravasation,
subsequent attachment to distal endothelium, and finally extravasation into a secondary
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tissue. In addition to the recruitment of new blood vessels, tumors also promote the
formation of new lymphatic vessels, or lymphangiogenesis. As such, proximal lymph
nodes are often the primary sites of metastasis. Our recent study showed that lymph node
ECs express VCAM-1, which was important for tumor-lymphatic EC interactions [65].
FAK inhibition reduced VCAM-1 expression both in lymph nodes and human dermal
lymphatic ECs, which were associated with reduced lymph node metastasis and tumorEC attachment [65]. These studies demonstrate the important role FAK plays in both
vascular and lymphatic ECs in the promotion of both tumor growth and subsequent
metastasis.
Tumors can develop resistance to chemotherapies, which can make them more
aggressive and can lead to decreased patient survival. The TME can promote
chemoresistance by providing a favorable environment for the cancer cells. FAK
expression in ECs has been shown to protect tumor cells from DNA damaging therapies
such as doxorubicin and irradiation [66]. However, loss of FAK increased cancer cell
sensitivity to DNA damaging therapies, and this was potentially through the loss of ECderived cytokines and chemokines that induced survival signaling within the tumor cells.
Mechanistically, it seems that EC FAK is required for DNA damage-induced NF-kB
activation and cytokine production. While this study suggests that FAK expression in
ECs is important for promoting chemoresistance, it is still unknown if this was through
FAK catalytic activity or through its kinase-independent scaffolding functions.
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The role of FAK in cancer-associated fibroblast (CAFs) and extracellular matrix (ECM)
Cancer-associated fibroblasts (CAFs) are the primary stromal cell found within
the TME. CAFs help facilitate pleiotropic events including tumor cell initiation, survival,
proliferation, and metastasis through the production and secretion of various cytokines,
growth factors, hormones, and extracellular matrix (ECM) proteins (reviewed in [67]).
Increased expression of the ECM protein lumican by gastric CAFs was shown to activate
FAK via b1 integrin to promote the proliferation, migration and invasion potential of
gastric cancer cells [68]. Recent reports suggest that pancreatic ductal adenocarcinoma
(PDAC) cells can activate CAFs and promote the expression of type I collagen [69].
Increased type 1 collagen expression promoted the cancer stemness of PDAC cells
through b1 integrin-FAK signaling [70]. Pharmacological inhibition or shRNA
knockdown of FAK in PDAC cells reduced type I collagen-mediated cancer cell
stemness [70]. The importance of FAK in PDAC cell stemness was further supported by
overexpression of either active wild-type (WT) or inactive Y397F FAK in PDAC cells.
Overexpression of FAK-WT, but not FAK-Y397F, led to increased tumor incidence even
when as few as 500 cells were injected into severe combined immunodeficient (SCID)
mice, suggesting that FAK activity is important to drive cancer cell stemness and
recruitment of CAFs [70]. It was shown that PDACs develop resistance to FAK inhibitors
because of CAF depletion and reduced collagen deposition [71]. This chemoresistance
was found to be due to decreased secretion of TGF-b by CAFs, which led to increased
activation of STAT3 signaling [71]. The importance of FAK in CAFs was further studied
through the use of a fibroblast-specific FAK knockout mouse model where the loss of
FAK in CAFs led to decreased breast cancer metastasis [72]. This study found that
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exosomes isolated from FAK-null CAFs contained elevated levels tumor-suppressing
microRNAs miR-16 and miR-148a [72], suggesting that FAK expression in CAFs may
play a role in exosome-mediated regulation of cancer cells. Further studies are needed to
evaluate the importance of FAK activity and/or localization on CAFs influence on tumor
progression, survival, and metastasis.
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CHAPTER II:
NUCLEAR FAK PROMOTES EXPRESSION OF TUMOR SUPPRESSOR GENE:
SUPPRESSOR OF CYTOKINE SIGNALING 3 (SOCS3) IN B16F10 MELANOMA

BY
Yelitza A. Rodriguez-Rodriguez, James Murphy, Kyuho Jeong, Eun-Young Erin Ahn,
and Ssang-Teak Steve Lim
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Summary
Cutaneous melanoma is a type of skin cancer that originates from the abnormal
proliferation of melanocytes. Although this type of cancer represents only 1% of the skin
cancer diagnosed yearly it accounts for most of the skin cancer- related deaths. This is in
part to its highly proliferative and invasive capacity. Current therapies include tumor
extirpation leaving untreated microscopic lesions that often leads to tumor recurrence and
display remarkable resistance to common chemotherapies. Thus, the discovery of
druggable targets that can reduce melanoma tumor growth are needed. Here we explored
the role of focal adhesion kinase (FAK) in melanoma proliferation and viability. We
found that B16F10 melanoma displays highly active and cytosolic restricted FAK. FAK
inhibition (FAK-I), prompted FAK nuclear localization. Nuclear FAK was able to bind
and ubiquitinate DNA methyltransferase 3A (DNMT3A). Loss of DNMT3A reduced
global DNA methylation with farther the expression of tumor suppressor gene,
suppressor of cytokine signaling 3 (SOCS3), which blocked proliferation of B16F10 and
reduced B16F10 viability. FAK-I also blocked B16F10 melanoma ear tumor growth and
reduced DNMT3A expression in vivo. Overall, we showed that FAK subcellular
localization plays a key role in determining the proliferative capacity of B16F10.
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Introduction
Skin cancer is the most common cancer type in the United State of America
(USA) [73]. Skin cancer is classified in three types based on the cell type within the
epidermis that it originates: basal cell carcinoma (BCC), squamous cell carcinoma (SCC)
and cutaneous melanoma (Supplemental figure A1). First, BCC originates from the outer
part of the epidermis and is the most common of all skin cancer type, it is a slow-growing
tumor that rarely metastasizes [74]. Second, SCC originates from the keratinocytes and
displays a higher growth rate than BCC and in certain cases, they can metastasize [75].
Lastly, melanoma is originated from melanocytes which are the cells in charge of
generating pigmentation of the skin. Melanoma accounts only for 1% of the skin cancer
annual incidence but due to its highly proliferative, aggressive and metastatic phenotype,
it is accounted for most of the skin cancer-related deaths [76].
Cutaneous melanoma can initiate as benign nevi, which is an agglomeration of
melanocytes that lack the ability to invade or metastasize [77]. However, changes in the
transcriptional landscape of the melanocytes within the nevi can grant these the ability to
increase the proliferative rate, invasiveness, and metastatic potential. One of the
hallmarks of these epigenetic changes is aberrant DNA methylation [78]. DNA
methylation is the modification of cytosines bases at the 5’- position of cytosine (5-mC)
in CG dinucleotides of CpG islands [79], and is usually read as gene silencing
modification. DNA methylation is carried out by DNA methyltransferases (DNMTs)
[80,81].
The family of DNMTs, capable of methylating cytosine bases, is composed of three
members: DNMT1, DNMT3A and DNMT3B. Each of these members has different
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functions, DNMT1 main role is to maintain DNA methylation of the newly synthesized
DNA strand during DNA replication [82]. On the other hand, DNM3A and DNMT3B are
responsible for de novo DNA methylation, which plays a major role in gene expression
[82]. Antagonizing the DNMTs, the Ten-eleven translocation (TET) enzymes, oversee
the demethylation of 5-mC to 5-hydroxymethylcytosine (5-hmC). There are three known
TETs (TET1-3) and the expression of these have been shown to be reduced in some
cancer and specifically in cutaneous melanomas, almost 20% of the melanoma patient
carry a TET mutation [83].
Typically, cancers cells including melanoma, display hypermethylation in the
promoter region of tumor suppressor genes, which prevents the expression of genes that
would normally block tumor initiation, growth and survival (Table 1) [78]. Particularly,
the silencing of certain members of the suppressor of cytokine signaling (SOCS) family
has been linked with poor prognosis and decreased patient survival [84]. The SOCS
family inhibits cytokine responses and activation of the Janus kinase (JAK) and the signal
transducers and activators of transcription (STAT) pathway. JAK/STAT signaling
pathway is initiated by the activation of receptor tyrosine kinases followed by binding of
their respective ligands such as cytokines, growth factors, interferons, and interleukins.
Upon activation JAK/STAT pathway can regulate gene sets that promote proliferation
and cell survival of a variety of cells. Also, JAK/STAT pathway can promote the
expression of SOCS family members which acts a feedback inhibitor of JAK/STAT
pathway [85]. The SOCS family is composed of eight members SOCS1-7 and Cytokineinduced SH2-containing domain protein (CIS) (Figure 4) [97]. Structurally, SOCS family
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Table 1. Tumor suppressor genes silenced by DNA methylation in melanoma.
Gene
PTEN
p16
p14

Function
Blocks PI3K
signaling
Inhibits CDK4/6
Inhibits MDM2

RASSF1A Cell cycle
regulation
SOCS3
Blocks cytokine
signaling

Promoter status Associated changes
Hypermethylated Gene transcription
silenced
Hypermethylated NRAS mutation
Hypermethylated Gene transcription
silenced
Hypermethylated Loss of expression

Reference
[78,86,87]

Hypermethylated Loss of expression

[95,96]

[88-90]
[91,92]
[93,94]

members share a conserved N-terminal domain (variable in length and homology across
the members), followed by a Scr homology domain (SH2) and a C-terminal SOCS motif
(which binds several ubiquitin ligases) [98]. SOCS family can inhibit cytokine signaling
in various ways: first, block STATs recruitment to the cytokine receptor by masking
STAT binding sites of the receptor, secondly, target proteins for proteasomal degradation
via ubiquitination, and thirdly, bind to JAKs and inhibit their kinase, and/or they can
target JAKs for degradation via the proteasome (Figure 4) [99]. The roles of each of the
members can be distinguished as follows: CIS and SOCS1-3 and a shorter N-terminal
domain and are usually transcribed rapidly after cytokine stimulation [100,101]. On the
other hand, SOCS4-7 have an elongated N-terminal domain and are expressed all the
time [101,102]. SOCS1-3 deficient mice display lethal phenotypes, as result from
uncontrolled activation of cytokine and growth factor pathways [103-105]. SOCS1 and 3
have been shown to display hypermethylation of the promoter region in several cancers;
head and neck cancer [106,107], lung cancer [108], prostate cancer [109] and in
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Figure 4. Domain architecture of the SOCS family.
(A) The eight SOCS proteins contain a central SH2 domain flanked by a variable Nterminal region and a C-terminal SOCS box. The SOCS are arranged as pairs based on
the relative domains compositions between their ESS and SH2 domains. All eight
members share a central SH2 domain, extended SH2 domain (ESS), and a C-terminal
SOCS box. In addition, SOCS1 and SOCS3 possess a kinase inhibitory region (KIR)
that serves as a pseudo-substrate for JAKs, blocking JAK function. Only SOCS1
contains NLS. (B) A diagram of the extended interactions of SOCS with target
proteins. The SOCS box interacts with several ubiquitinating machinery enzymes i.e.,
Elongin B, Elongin C, Cullin-5 (Cul5), and Ring-box 2 (Rbx2), and an E2 ubiquitin
transferase.
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melanoma, which leads to transcriptional gene silencing and aggressive phenotypes of
tumors [110].
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase frequently
activated by integrins signaling and various transmembrane receptors such as G-protein
coupled, cytokine and growth factor receptors [21,111,112]. Once active, FAK promotes
various cellular processes that range from cell adhesion, migration, proliferation, to cell
survival. FAK have been shown to promote malignant features in various cancers, but in
particular melanoma, such as: tumor aggressiveness, tumor angiogenesis, fibrotic stroma
and chemotherapeutic resistance [47,65,113-115]. FAK can also translocate to the
nucleus and where is has been show to promote a more suitable pro-tumor landscape by
modulating immune tumor evasion and therapeutic resistance in some skin cancer
[14,46,53]. Although it is well established that FAK can go to the nucleus in melanoma
cells, little is known about the impact of nuclear FAK signaling in melanoma [23].
In the present study, we investigated the molecular mechanism of how FAK regulates
DNA methylation and tumor suppressor gene expression, determining melanoma fate
during tumor growth. Using pharmacological FAK inhibition invitro and in vivo models
of tumor model, we found that nuclear FAK decreases DNMT3A enzyme stability and
DNA methylation, leading to increased expression of the tumor suppressor gene SOCS3
which blocked melanoma proliferation.
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Materials and methods

Cells and reagents
Murine B16F10 cells were bought from American Type Culture Collection
(ATCC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 100mM Pen Strep (Gibco), 100mM sodium pyruvate, and 100mM non-essential
amino acids. A small molecule FAK inhibitor, PF-04554878, (VS-6063), was obtained
from MedKoo. Anti-FAK (#05-537 clone 4.47) and anti-GAPDH (#MAB374) were
obtained from Millipore. Anti-FAK pY397 (#44-624G) for blotting, was obtained from
Invitrogen. Anti-SOCS3 (sc-9023, H-103) and anti-DNMT3A (sc-365769, C-12) were
obtained from Santa Cruz Biotech. Anti-β (A5441) actin was purchased from Sigma
Aldrich.
Cell viability assay
5x104 B16F10 melanoma cells were seeded in each well of 96-microwell plate
and with FAK-I (VS-6063, 2.5 µM), vehicle or Doxycycline (1 µg/mL) for the indicated
times. After 4 h incubation, the absorbance of resazurin was measured at 570 nm and 600
nm using Luminesce mode microplate reader (BioTek, Winooski, USA). Each
experiment was done in triplicate.
Animal experiments
Animal experiments were approved by and performed in accordance with the
guidelines of the University of South Alabama Institutional Animal Care and Use
Committee. Both C57BL6 male and female mice (6- to 8-weekold) were used for mouse
ear orthotopic tumor model. Ear orthotopic tumor was used as previously described, with
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some minor modifications [116]. Briefly, mice were injected in the ear pinnacle with
500,000 B16F10 cells. After 8 days, mice were treated twice daily with either vehicle (30
% [2-Hydroxypropyl]-β-cyclodextrin/3 %dextrose, Sigma) or the FAK inhibitor VS-6063
(30 mg/kg), twice daily by oral gavage. At day 14, mice were anesthetized with ketamine
and xylazine, and tissues were collected for blotting, staining, DNA and RNA isolation.
Immunoblotting
RIPA buffer (pH 7.4) that included 50 mM HIPES, 150 mM sodium chloride, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 10% glycerol, and Complete
Protease Inhibitor Cocktail (Roche, Mannheim, Germany) was used to lysate cells and
tissue. Lysates were cleared by centrifugation, and supernatants were boiled in SDS
loading buffer. Samples were separated by SDS polyacrylamide gel electrophoresis
(PAGE) and transferred to PVDF membrane. The membranes were blocked and
incubated with indicated antibodies overnight. Next day the membranes were washed
with TBST buffer (50mM Tris pH7.5, 150 mM NaCl, 0.05% Tween-20) three times and
incubated for 1 h at room temperature (RT) in HRP-conjugated secondary antibody. The
immunoblot were washed three more washes in TBST, and the membranes were
developed using ECL solution and the signal was detected using Biorad imager.
Immunohistochemistry
Fresh tissue collected from mice were embedded in Optimal Cutting Temperature
(O.C.T.) compound (Tissue Tek) and frozen sections (7 μm) were generated for
immunohistochemistry. Slides were then fixed in 4% paraformaldehyde, washed in PBS,
and subsequently incubated in blocking solution (0.01% Triton X-100, 1% BSA, and 1%
goat serum in PBS) for 1 h at room temperature. Sections were incubated anti-FAK
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(1:200), anti-pY397 FAK (1:100), anti-SOCS3 (1:100), or anti-DNMT3A (1:100)
overnight at 4 °C. The slides were washed in PBS and a secondary fluorescent antibody
was added for 1 h at room temperature. Images were visualized using Nikon A1R
confocal microscope (Nikon). Microscope images were processed by using Photoshop
CS5.
Immunoprecipitation
Cells were lysed with Triton buffer that includes 1% Triton X-100, 50 mM
HEPES, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 10 mM sodium pyrophosphate, 100
mM sodium fluoride, 1 mM sodium orthovanadate, and protease inhibitors. Lysates were
cleared by centrifugation, and equal amounts of proteins were subjected to
immunoprecipitation. The lysates were rotated overnight at 4°C, then protein G or A
agarose beads were added, and the mixture was rotated for 2 hat 4°C. The
immunoprecipitates were washed three times with Triton buffer and suspended with 2X
SDS-loading buffer and boiled at 98℃ to elude protein from the beads. Samples were
separated by SDS-PAGE and immunoblotted.
Generation of stable cell lines
B16F10 cells were incubated with purified lentivirus of pLentilox 3.7 Scramble
(ShScr) or DNMT3A (shDNMT3A) shRNAs. After 48 h, B16F10 were selected with
puromycin (2 µg/ml). Stable expressing cells were then used for experiments.
Generation of plasmid constructs and lentivirus production
Plasmid for the tetracycline inducible system pMA3211 was a gift from Mikhail
Alexeyev & Troy Stevens (Addgene plasmid # 46879; http://n2t.net/addgene:46879;
RRID:Addgene_46879) [117]. SOCS3 was PCR amplified from B16F10 cDNA using the
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primers listed on Table 2. PCR fragment was digested and ligated using XbaI and BamHI
restriction site in vector. Lentivirus was produced using a third-generation packaging
system in HEK 293FT cells. At 72 hours after transfection, lentivirus-containing medium
was centrifuged to remove cell debris and passed through a 0.45-µm filter. Lentivirus was
concentrated by ultracentrifugation at 25,000 rpm for 1.5 hours using SW40-Ti rotor
(Beckman Coulter, Brea, CA). Supernatant was removed and lentivirus pellet was
resuspended in sterile PBS. Lentivirus was divided into aliquots and stored at −80°C until
used.
Genomic DNA dot blot
To extract genomic DNA (gDNA) from B16F10 cells or tumors using QIAamp
DNA mini kits according to the manufacturer's instructions (Qiagen). gDNA samples
were diluted with 2 N NaOH and 10 mM Tris-HCl, pH 8.5, and then loaded on
Amersham Protran Nitrocellulose membranes 0.2 µm (GE Healthcare) using a 96-well
dot-blot apparatus (Bio-Rad). After being dried at RT for 1h and gDNA was crosslinked
to the membrane using GS Gene Linker (Bio-Rad, Hercules, CA), then blocked with 5%
nonfat milk in TBST for 1h at RT. Membranes were incubated in primary antibodies
against 5-mC or 5-hmC at 4 °C overnight. These were visualized by using an ECL
solution. To ensure equal loading, membranes were stained with methylene blue (0.02%)
after immunoblotting and colorimetric pictures were captured using the Biorad imager.
RNA extraction and real-time quantitative polymerase chain reaction (RT-qPCR)
For total RNAs extraction we used RNeasy kit (Qiagen) and converted to cDNA
using random hexamers and Superscript III (Life Technologies, Carlsbad, CA). Real-time
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quantitative polymerase chain reaction (RT-qPCR) was performed using iTaq Universal
SYBR Green SMX and CFX Connect real time system (Bio-Rad). PCR primers were
listed in Table 2.
Statistical analysis
Data sets underwent Shapiro-Wilk test for normality, and statistical significance between
experimental groups was determined with student t-test or two-way analysis of variance
(2-way ANOVA) with Sidak multiple comparisons test (Prism software, v7.0d; GraphPad
Software, La Jolla, CA). Power analyses were performed to determine sample size for 2way ANOVA.
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Table 2. DNA oligonucleotides used in Chapter II.
Primer
GAPDH

Sequence
Forward: 5¢–GGTGCTGAGTATGTCGTGGAGTCTA–3¢
Reverse: 5¢–AAAGTTGTCATGGATGACCTTGG–3¢
DNMT3A
Forward: 5¢– ACGGCAATTCCTTCTCTGAA–3¢
Reverse: 5¢– ACGGTTCTCCTCCTGTTCCT–3¢
18S
Forward: 5¢– TAGAGGGACAAGTGGCGTTC –3¢
Reverse: 5¢– CGCTGAGCCAGTCAGTGT –3¢
SOCS3
Forward: 5¢–CTTTTCTTTGCCACCCAC–3¢
Reverse: 5¢–GTTGACAGTCTTCCGACA–3¢
Tet-On SOCS3 mSOCS3 Fwd XbaI:
5’-AAATCTAGAAATGGTCACCCACAGCAAGTTT–3¢
mSOCS3 Rev BamHI:
5’-AAAGGATCCAATTAAAGTGGAGCATCATACTG–3¢
shDNMT3A-1 5’-TGTTTCATACTTGGGAGGCTTTCAAGAGAAGCCT
CCCAAGTATGAAACTTTTTTC–3¢
shDNMT3A-2 5’-TCGAGAAAAAAGTTTCATACTTGGGAGGCTTCTC
TTGAAAGCCTCCCAAGTATGAAACA–3¢

Results

Pharmacological FAK inactivation (FAK-I) reduces DNMT3A protein levels in B16F10
melanoma
To explore the function of FAK subcellular localization in melanoma progression,
we monitored FAK subcellular localization under vehicle or FAK inhibitor (FAK-I)
treated B16F10 melanoma for 48 hours (hrs). Vehicle-treated groups presented abundant
active (pY397 FAK mark) and cytosolic- localized FAK (Figure 5A, top panel).
Exposure of B16F10 cells to FAK-I reduced active FAK and prompted nuclear FAK
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Figure 5. FAK inhibition promotes nuclear FAK localization and reduces DNMT3A
expression in B16F10 melanoma.
(A)B16F10 melanoma cells were treated with/without FAK inhibitor (FAK-I, VS-6063,
2.5 µM) for 48 hours (hrs). Immunofluorescence staining for FAK (green) and pY397
FAK (red) are shown. Merge: green, red and DAPI (blue) (B) B16F10 were treated
without FAK-I (VS-6063, 2.5 μM) for the indicated time points and cells counts at each
timepoint are shown. (C) B16F10 cells were treated with FAK-I (VS-6063, 2.5 µM) for
the indicated timepoints. Cells viability was evaluated by resazurin oxidation (n=3, +/SEM). (D) B16F10 melanoma were treated with FAK-I (VS-6063, 2.5 µM) for the
indicated timepoints. Cells were lysate and analyzed by western blot. Immunoblotting of
FAK, pY397FAK (active FAK), DNMT3A and β-actin as loading control are shown. (E)
B16F10 cells were treated with FAK-I (VS-6063, 2.5 µM) for the indicated timepoints
and mRNA of DNMT3A (n=3, +/-SEM) was measured by RT-qPCR. *** p<0.001, ns
p>0.05 compared to vehicle.
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Day 2

localization (Figure 5A, bottom panel). Nuclear FAK also reduced B16F10 proliferation
(Figure 5B) and viability (Figure 5C). In one of our recent manuscripts, we demonstrated
that nuclear-localized FAK plays a major role in controlling the proliferation of vascular
cells, particularly, in smooth muscle cells (SMC) [118]. In this setting, nuclear-localized
FAK was able to bind and target DNMT3A for proteasomal degradation, leading
significant reduction in the expression of genes that dictate the phenotypic traits of
SMCs. FAK-mediated loss of DNMT3A blocked proliferation by regulating epigenetics
of SMCs, we wanted to explore if this signaling axis could also regulate the proliferative
potential of B16F10 melanoma. We evaluated DNMT3A expression under FAK-I and
observed that FAK-I reduced DNMT3A protein expression (Figure 5D) while no change
in mRNA levels of DNMT3A were observed (Figure 5E).
Nuclear FAK binds DNMT3A in B16F10 melanoma
To explore the possibility of FAK and DNMT3A association we performed FAK
immunoprecipitation (IP) in B16F10 treated with vehicle or FAK-I for 6 hrs. FAK-I
reduced total DNMT3A in the input (Figure 6A). Also, FAK-I promoted FAK-DNMT3A
interaction (Figure 6B). Since nuclear FAK reduced DNMT3A protein in the input and
nuclear inactive FAK has been shown to regulate the stability of certain nuclear proteins
by ubiquitination and subsequent proteasomal degradation [11,12], we wanted to explore
if co-treatment of FAK-I with MG132 (proteasomal inhibitor) could prevent FAKmediated reduction of DNMT3A. FAK-I and MG132 cotreatment was able to block the
reduction of DNMT3A seen in the FAK-I alone lane (Figure 6A). As well cotreatment
increased FAK and DNMT3A interaction (Figure 6B).

37

Nuclear FAK promotes ubiquitination of DNMT3A in B16F10 melanoma
Since the proteasome inhibitor, MG132, was able to block FAK-mediated
DNMT3A degradation, we explore the possibility of FAK mediating DNMT3A
ubiquitination. For this, we performed DNMT3A IP under the same conditions
mentioned before (Figure 7A) and explored the DNMT3A ubiquitination status by
probing DNMT3A IP membrane with ubiquitin antibody. FAK-I increased ubiquitination
of DNMT3A and combination (FAK-I and MG1232) treatment further increased
DNMT3A ubiquitination (Figure 7B). Since DNMT3A function is to promote DNA
methylation I checked the impact of FAK-I in DNA methylation by checking global
DNA methylation status. FAK-I reduced DNA 5- mC (Figure 8A) while no change in 5hmC (Figure 8B). Since DNA methylation is a marker usually associated with the
inactivation of gene expression [119] I looked up genes that were frequently silenced by
methylation in cancer and simultaneously, reduced proliferation and tumor progression.
Tumor suppressor genes are a subset of genes that are commonly methylated in cancer
Nuclear FAK regulates epigenetics changes in B16F10 melanoma
Since the principal role of DNMT3A is to regulate de novo methylation of CpG
islands, we wanted to explore the impact of nuclear FAK- mediated loss of DNMT3A in
DNA methylation. To do so, we used a DNA dot plot and investigated changes in global
DNA methylation. FAK inhibitor reduced DNA 5-mC mark (Figure 8A) and increased
[120]. Out of the top tumor suppressor genes regulated by DNA methylation see Table 1,
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Figure 6. FAK inhibition promotes DNTM3A-FAK interaction.
(A) B16F10 melanoma cells were treated with FAK-I (VS-6063, 2.5 μM) only or
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we decided to focus on SOCS3 because its expression not only impacts tumor cell
growth, but it can also block other steps in tumor progression such as angiogenesis [121]
and immune cell recruitment [122]. B16F10 cells were treated with FAK-I and SOCS3
expression was monitored. FAK-I in addition to reducing DNMT3A protein stability it
increased SOCS3 protein (Figure 9A) and mRNA expression (Figure 9B).Since FAK-I
can impact several aspects of the cell we wanted to explore the specific impact of SOCS3
expression in B16F10 melanoma. For this matter, we used a Tetracycline-inducible
system (Tet-On) where SOCS3 expression was under the tetracycline inducible promoter.
We used RT-qPCR and western blot to validate the system, we observed and steep
increase in SOCS3 mRNA and protein in the presence of Doxycycline (Dox), a
tetracycline analog (Figure 10A and B). We explore the impact of tetracycline alone in
SOCS3 expression in cells expressing empty vector and observed no significant impact in
SOCS3 expression by Dox (Supplemental figure 44). Tet-On SOCS3 expression
markedly decreased B16F10 proliferation (Figure 10C) and decreased cell viability
(Figure 10D).
DNMT3A regulates SOCS3 expression
To evaluate the impact of DNMT3A in SOCS3 expression we stably knockdown
(KD) DNMT3A, from now on referred to as DNMT3A-KD, in B16F10 cells. We
validated the efficacy of the DNMT3A-KD by western blot (Figure 11A) and RT-qPCR
(Figure 11B). In both instances we observed a statistically significant reduction in
DNMT3A protein and mRNA. SOCS3 expression was upregulated in shDNMT3A cells
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compared to scramble control (shScr) protein (Figure 12A) and mRNA (Figure 12B) in
shDNMT3A expressing cells. We also observed a marked reduction in proliferation
under DNMT3A-KD (data not shown).
FAK inhibitor reduced B16F10 melanoma tumor growth
To explore the impact of FAK-I in melanoma growth we grew B16F10 melanoma
in the ear pinnacle of C57BL6 mice. After tumors were established and size-matched we
started the FAK-I regiment twice a day by oral gavage (Figure 13A). FAK-I significantly
blocked B1610 melanoma growth (Figure 13B) and overall tumor weight (Figure 13C).
We used ear tumor lysates to evaluate the efficacy of FAK-I in reducing DNMT3A
protein stability and promoting SOCS3 expression in vivo. FAK-I treatment reduced
DNMT3A, and increased SOCS3 protein expression (Figure 14A) in tumor cells. No
statistical significance in DNMT3A mRNA (Figure 14B) was detected but a steep
increase in FAK and prompted FAK nuclear localization (Figure 15). Additionally, FAKI increased SOCS3 expression and reduced DNMT3A expression (Figure 16) in vivo.
I wanted to study the clinical impact of FAK localization in melanoma in human
samples. FAK-I reduced DNMT3A expression and increased SOCS3 protein (Figure
SOCS3 in tumor was observed (Figure 14C). I evaluated changes in FAK subcellular
localization in tumor cryosections by immunofluorescence staining. Vehicle treated mice
exhibit cytosolic localized and highly active FAK while FAK-I treatment reduced active
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Figure 17. FAK inhibition promotes SOCS3 expression and decreases viability of
human melanoma.
(A) A375 human melanoma were treated with FAK-I (VS-6063, 2.5 µM) for the
indicated timepoints. Cells were lysates and analyzed by western blot. Immunoblotting
of FAK, pY397FAK (active FAK), DNMT3A and β-actin as loading control are
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evaluated by resazurin oxidation (n=3, +/-SEM). ns p>0.05, *** p<0.001 vs vehicle.
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DAPI (blue).
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Figure 19. Human melanoma tumor expresses low levels of SOCS3.
Human biopsies were embedded were fixed and embedded in OCT or parafilm.
Cryosections of biopsies from melanoma and normal adjacent tissue were analyzed by
immunofluorescence. DNMT3A (green) and SOCS3 (red). Merge: Green, red, and
DAPI (blue).
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Discussion
In this study, we explored the role of FAK subcellular localization in tumor cell growth.
The nuclear FAK-DNMT3A axis regulated the expression of the tumor 17A) and mRNA
(Figure 17B) in A375 human melanoma cells. We analyzed skin biopsies of human
melanoma tumors and compared FAK localization and activation to adjacent normal skin
of the same patient. Concomitant with our observation from mouse experiments, the
lesion site displayed highly active and cytosolic-localized FAK while samples from
normal skin exhibit mixed FAK localization with abundant nuclear-localized FAK
(Figure 18). Similarly, we also observe abundant DNMT3A expression in the human
melanoma biopsies and very little SOCS3 expression in the lesion areas (Figure 19).
Tumor suppressor gene SOCS3 which dictated the proliferative potential and viability of
tumors cells (Figure 20). While in growing conditions FAK localization was
predominantly cytosolic, pharmacological FAK inhibition (FAK-I) prompted nuclear
FAK localization. Although FAK possesses an intrinsic nuclear localization sequence
[11], nuclear localization seems to be dependent on FAK activation this coming from the
fact that in B16F10 we only observed nuclear FAK in cells treated with FAK-I. This is
consistent with our previous observations that vehicle-treated SMCs in vitro exhibit
abundant cytosolic and active FAK, but FAK-I prompted nuclear FAK localization,
which blocked SMC proliferation by various mechanisms [118,123]. Although we failed
to detect active nuclear-localized FAK (pY397 FAK), some groups have reported that
certain cancer cells exhibit abundant active nuclear FAK [14,31,124]. These differences
in FAK localization and activity patterns could possibly be explained by the copy number
variations of FAK gene, PTK2 in different cancer cells lines. This means that some
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cancer might display abundant nuclear FAK because these cells express more FAK than
others and active FAK protein can “breakthrough” the nuclear compartment of the cell.
Also, it would be interesting to explore the underlying mutations (in these cells that
display highly active FAK) and look at the expression of the phosphatases and upstream
kinases reported to phosphorylate or dephosphorylate FAK and evaluate their expression
and activity. As well, some of the groups that have reported active nuclear FAK derive
their conclusions from FAK rescue experiments (using a lenti-viral system to express
FAK in FAK knockout cells) [14,46]. In this case, nuclear active FAK could be an
artifact of overexpressing FAK.
Nuclear inactive FAK reduced DNMT3A protein stability by promoting
DNMT3A proteasomal degradation. The loss of DNMT3A lead to a significant reduction
in 5-mC levels, this modification of cytosine bases is a marker associated with repression
of gene expression [80] and has been shown to negatively regulate the expression of
tumor suppressor genes in melanoma [78]. DNA hypomethylation promotes the
expression of tumor suppressor genes such as SOCS3. SOCS3 expression has been
shown to regulate several steps of tumor progression [95,96,110,121,122] and here we
showed that SOCS3 blocked B16F10 proliferation and viability. Further knockdown, of
de novo DNA methylase DNMT3A, revealed that DNMT3A is responsible for the
silencing of SOCS3 in B16F10 melanoma.
Most importantly, from our in vivo tumor experiments, FAK was localized to the
cytosol within most of the cells within the TME and FAK active marker was abundant in
the TME. As tumor cells growth they can recruit and activate the TME, which would
generate a more suitable TME. Here, we showed that promoting nuclear FAK
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localization decreased DNMT3A protein in vivo and increased SOCS3 expression.
Although it was not explored in this chapter, we have observed that nuclear FAK reduced
tumor-associated angiogenesis (recruitment of endothelial cells), which suggests that
nuclear FAK localization is needed to block communication between TME and tumor
cells. In human skin biopsies, FAK was localized to the nucleus in normal skin samples
but, the lesion section exhibits mixed FAK localization, but the majority of FAK was
localized to the cytosol. In the skin FAK is mostly localized to the nucleus, here FAK can
con control the proliferative state of skin cells, and melanocytes by destabilizing
DNMT3A protein. This helps to keep DNA methylation low and maintaining SOCS3
expression up this expression pattern seems to correlate with longer survival
(Supplemental figure A3). Once cells accumulate enough mutation that allows them to
bypass low proliferative rates, FAK localization is shifted from the nucleus to the cytosol.
Once in the cytosolic compartment of the cell, FAK can respond and phosphorylate
downstream targets promoting proliferation and tumor progression.
Taken the mouse data and human data, it seems that nuclear-localized FAK ‘rewires’ the cell from a pathogenic state (cancer) to normal skin epithelium. Although this
study didn’t explored the expression of markers of normal epithelial, it would be
interesting to see if nuclear FAK reduced the expression of melanoma markers such as
tyrosinase [125]. Also, there are other important tumor suppressor candidates that were
not explored in this chapter that might be increased by FAK-I. They are a few questions
that remained unanswered such as the methylation status of SOCS3 promoter, for this we
will need to do bi-sulfide sequencing.
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Figure 20. Model: Nuclear FAK promotes the expression of tumor suppressor
gene SOCS3.
Graphical summary. Soluble factor from the TME promote FAK-activation and
cytosolic localization. This promotes FAK localization to the cytosolic fraction of the
cells, thus prolonging DNMT3A expression and methylation of tumor suppressor genes
such as SOCS3. Under FAK-I, FAK loss its tyrosine phosphorylation and promotes
FAK nuclear localization. Once in the nucleus FAK binds and promotes ubiquitination
and degradation of DNMT3A. Loss of DNMT3A expression results in DNA
hypomethylation in the promoter region of SOCS3 thus allowing its expression.
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CHAPTER III:
NUCLEAR FAK PREVENTS ANGIOGENESIS VIA REDUCED EXPRESSION
OF HEPARIN BINDING EPIDERMAL GROWTH FACTOR (HB-EGF)

BY
Yelitza A. Rodriguez-Rodriguez, James Murphy, Kyuho Jeong, Eun-Young Erin Ahn,
and Ssang-Teak Steve Lim
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Summary
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that acts as a primary
nexus of extracellular signals from integrins and growth factor receptors that help to
sustain endothelial cells (ECs) migration, proliferation, and survival processes vital for
angiogenesis. Angiogenesis is the development of new vessels from preexisting
vasculatures and is the underlying root of multiple pathologies such as cancer. FAK
inhibitors (FAK-I), in addition of promoting FAK nuclear localization, have been proven
beneficial in intervening with ECs growth. However, the impact of FAK localization in
ECs pathological angiogenesis is poorly understood and is the focus of this chapter. We
observed that genetic and pharmacological FAK inactivation blocked vascular
endothelial growth factor (VEGF)/ fibroblast growth factor (FGF)-induced Matrigel plug
angiogenesis in vivo. FAK-I reduced protein of major regulators of angiogenesis
including heparin-binding epidermal growth factor (HB-EGF) in an angiogenesis array.
FAK-I also reduced HB-EGF protein and mRNA in various mouse, human EC lines and
human infantile hemangioma cell lines, resulting in reduced EC proliferation. FAK-I also
reduced HB-EGF mRNA and protein in vivo angiogenesis. Mechanistically, FAK binds
to and phosphorylates YAP, which enhances HB-EGF expression. Loss of YAP tyrosine
phosphorylation following FAK inhibition decreased YAP nuclear localization and
protein stability.
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Introduction
Focal adhesion kinase (FAK) is a protein tyrosine kinase that controls fundamental
cellular processes, including cell adhesion, migration, proliferation, and survival
[9,11,126] downstream of various transmembrane receptors: integrins, G-proteincoupled, cytokine, and growth factor receptors [8-10]. Upon integrin or growth factor
receptor signaling, FAK is activated and autophosphorylated at tyrosine (Y) 397 [127]. In
addition to the roles of FAK in mediating signaling cascades downstream of integrins and
other receptors at the plasma membrane, recent studies demonstrated that FAK could
translocate to the nucleus. FAK contains a nuclear localization sequence (NLS) within
the FAK FERM domain and a nuclear export sequence (NES) within the kinase domain,
allowing FAK to shuttle between the cytosol and the nucleus [11,18]. Based on these
features, FAK signaling can be dissected into two categories: cytosolic and nuclear [128].
FAK's cytosolic signaling is heavily dependent on increased FAK activity and includes:
signaling cascades downstream of multiple transmembrane receptors, which ultimately
enhance focal adhesion turnover, cell adhesion, cell migration, and gene expression in
response to extracellular signals [31,128-131]. On the other hand, far less characterized,
nuclear FAK may act as a critical player in regulating gene expression, independently of
its catalytic functions for most cases [128,132,133].
Endothelial cell (ECs) proliferation, migration, and survival are critical events for
angiogenesis [134]. Previous studies using FAK global knockout (KO), EC-specific FAK
KO, global FAK kinase-dead (KD), EC-specific FAK KD or FAK Y397F (tyrosine to
phenylalanine)-autophosphorylation mutant mouse models demonstrated that FAK
expression and activity are vital for developmental angiogenesis [135-140]. These
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mutations in mice lead to an embryonic lethality phenotype because of profound vascular
defects [141]. Vascular endothelial growth factor (VEGF) is a crucial factor in promoting
angiogenesis, and EC-specific FAK-KO mouse exhibits reduced VEGF responsiveness,
as a result from the reduced EC proliferation and increased EC death [142]. FAK also
regulates vascular barrier function by modulating EC adherents junctions (AJs) [143].
During development, global or EC-specific FAK KD expression results in disorganized
EC patterning and defective blood vessel morphogenesis [138]. It is noted that FAK
expression is upregulated in vasculatures surrounding tumors [57]. Further, experimental
angiogenesis studies have revealed that EC-specific, KD, or Y397F FAK mutants lead to
reduced tumor growth due to reduced angiogenesis [59]. Also, EC-FAK contributes to
adjuvant therapy resistance by promoting the secretion of chemokines that drive tumor
cell survival following doxorubicin and irradiation therapies [66]. Interestingly, FAK
nuclear localization and its kinase activity were critical for VEGF receptor 2 (VEGFR2)
transcription, where FAK binds to VEGFR2 promoter following VEGF treatment in
mouse ECs [61]. Recently, we demonstrated that FAK is prominently localized to the
nucleus of vascular smooth muscle cells (SMCs) and ECs in vivo under a normal
condition [12]. Nuclear FAK in ECs and SMCs was not active, but exogenous
stimulation by wire injury or TNF-⍺ increased pY397 FAK marker and promoted FAK
cytosolic localization accompanied with enhanced proliferation and migration of EC [12].
Overall suggesting that deprivation of FAK nuclear localizationism is required for
migration and proliferation of EC. Despite the importance of FAK in ECs, little is known
about the potential role of FAK shuttling in ECs and its contribution to angiogenesis. The
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proposed study will shed light on the importance of the role of nuclear or cytoplasmic
FAK in angiogenesis.
Materials and methods

Cells and reagents
Human umbilical vein endothelial cells (HUVECs) and MS1 were bought from
American Type Culture Collection (ATCC). MS1 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 100mM PenStrep (Gibco),
100mM sodium pyruvate, and 100mM non-essential amino acids. HUVECs were
maintained in VascuLife VEGF media (LifeLine Cell Technologies). Cells between
passages 3 and 11 were used for experiments. A small molecule FAK inhibitor, PF04554878, 6063 (VS-6063), was obtained from MedKoo. Anti-FAK (#05-537 clone
4.47), anti 4G10 (#05321) and anti-GAPDH (#MAB374) were obtained from Millipore.
Anti-FAK pY397 (#44-624G), was obtained from Invitrogen. Anti-vWF (#271409) and
anti-YAP (#376830) were obtained from Santa Cruz Biotech. Anti-β (A5441) actin was
purchase from Sigma Aldrich.
Animal experiments
Animal experiments were approved by and performed in accordance with the
guidelines of the University of South Alabama Institutional Animal Care and Use
Committee. Both C57BL/6 male and female mice (6- to 8-week-old) were used for
Matrigel assay. Matrigel plugs experiments were used as previously described, with some
minor modifications [144]. Briefly, mice were injected subcutaneously on the flank with

63

200 μl BD-Matrigel Matrix-Phenol free (#356237) containing either sterile PBS or 400
ng/mL of human recombinant bFGF (PetroTech) and 400 ng/mL VEGF (PetroTech)
mixture. Mice were treated twice daily with either vehicle (30 % [2-Hydroxypropyl]-βcyclodextrin/3 %dextrose, Sigma) or the FAK inhibitor VS-6063 (30 mg/kg), twice daily
by oral gavage. After 7 days, mice were injected via tail vein with 20 µg FITCconjugated lectin (GSLI-BSL I, Vector Laboratories). At the endpoint, mice were
anesthetized with ketamine and xylazine and Matrigel plugs were removed,
photographed, fixed, embedded and cryosectioned were analyzed or flash frozen for
blotting or RNA isolation.
Immunoblotting
We used RIPA buffer (pH 7.4) that included 50 mM HIPES, 150 mM sodium
chloride, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 10% glycerol, and
Complete Protease Inhibitor Cocktail (Roche, Mannheim, Germany) to lysate cells and
tissue. Lysates were cleared by centrifugation, and supernatants were boiled in SDS
loading buffer. Samples were separated by SDS polyacrylamide gel electrophoresis
(PAGE) and transferred to PVDF membrane. The membranes were blocked and
incubated with indicated antibodies overnight. Next day the membranes were washed
with TBST buffer (50mM Tris pH7.5, 150 mM NaCl, 0.05% Tween-20) three times and
incubated for 1 h at room temperature (RT) in HRP-conjugated secondary antibody. The
immunoblot were washed three more washes in TBST, and the membranes were
developed using ECL solution and the signal was detected using Biorad imager.
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Immunohistochemistry
Fresh or fixed tissue collected from mice were embedded in Optimal Cutting
Temperature (O.C.T.) compound (Tissue Tek) and frozen sections (7 μm) were generated
for immunohistochemistry. Slides were then fixed in 4% paraformaldehyde, washed in
PBS, and subsequently incubated in blocking solution (0.01% Triton X-100, 1% BSA,
and 1% goat serum in PBS) for 1 h at room temperature. Sections were incubated antiFAK (1:200), anti-pY397 FAK (1:100), anti-vWF (1:400), or anti-YAP (1:500) overnight
at 4 °C. The slides were washed in PBS and a secondary fluorescent antibody was added
for 1 h at room temperature. Images were visualized using Nikon A1R confocal
microscope (Nikon). Microscope images were processed by using Photoshop CS5.
Immunoprecipitation
Cells were lysed with Triton buffer (l1% Triton X-100, 50 mM HEPES, 150 mM
NaCl, 10% glycerol, 1 mM EDTA, 10 mM sodium pyrophosphate, 100 mM sodium
fluoride, 1 mM sodium orthovanadate) and protease inhibitors. Lysates were cleared by
centrifugation, and equal amounts of proteins were subjected to immunoprecipitation.
The lysates were rotated overnight at 4°C, then protein G or A agarose beads were added,
and the mixture was rotated for 2h at 4°C. The immunoprecipitated were washed three
times with Triton buffer and suspended with 2X SDS-loading buffer and boiled at 98℃
to elude protein from the beads. Samples were separated by SDS-PAGE and
immunoblotted.
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RNA extraction and quantitative real-time quantitative polymerase chain reaction (RTqPCR)
For total RNAs extraction we used RNeasy kit (Qiagen) and converted to cDNA
using random hexamers and Superscript III (Life Technologies, Carlsbad, CA). Real-time
quantitative polymerase chain reaction (RT-qPCR) was performed using iTaq Universal
SYBR Green SMX and CFX Connect real time system (Bio-Rad). PCR primers were
listed in Table 3.

Table 3. DNA oligonucleotides used in Chapter III.
Primer
GAPDH
mouse YAP
18S
human YAP

Sequence
Forward: 5¢–GGTGCTGAGTATGTCGTGGAGTCTA–3¢
Reverse: 5¢–AAAGTTGTCATGGATGACCTTGG–3¢
Forward: 5¢– TAGAGGGACAAGTGGCG –3¢
Reverse: 5¢– CTTTTCTTTGCCACCCAC –3¢
Forward: 5¢– TAGAGGGACAAGTGGCGTTC –3¢
Reverse: 5¢– CGCTGAGCCAGTCAGTGT –3¢
Forward: 5¢– CTTTTCTTTGCCACCCAC–3¢
Reverse: 5¢– GTTGACAGTCTTCCGACA–3¢
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Results

Pharmacological FAK inactivation. (FAK-I) promotes nuclear FAK localization and reduces
endothelial cells (ECs) proliferation
To explore the impact of EC FAK subcellular localization in angiogenesis, human
umbilical vein endothelial cells (HUVECs) were treated with FAK inhibitor (FAK-I)
Under vehicle condition, FAK staining was localized to the cytosol and perinuclear space
of the cells and pronounced focal contacts. However, FAK-I treatment prompted FAK
nuclear localization (Figure 21A). To explore the impact of nuclear FAK localization in
ECs proliferation, which is one of the key contributors to angiogenesis, we treated
HUVECs with FAK-I and compared cell counts at each timepoint. FAK-I treated group
displayed a profound proliferation defect (Figure 20B). We explore the impact of FAK-I
concentration and toxicity in HUVECS to make sure that the changes in proliferation
observed were not due to increased cell death and that cells were viable after treatment.
Several concentrations of FAK-I were used and the efficacity of these in blocking FAK
activation was evaluated by western blotting (Supplemental figure A4a). Propidium
iodide (PI) was used to evaluate the cells undergoing apoptosis under several
concentrations of FAK-I (Supplemental figure A4b). PI is a fluorescence dye that is
impermeable for healthy cells, but the dye can get into apoptotic cells.
Nuclear FAK reduces the expression of multiple angiogenic factors in angiogenesis array
Since nuclear FAK localization prevented ECs proliferation, we wanted to
explore if nuclear FAK was able to modulate the expression of angiogenic growth factors
important in promoting EC proliferation. For this, we used an angiogenesis proteome
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profiler array (R&D Systems #ARY007) to interrogate the expression of over 55 factors
important in angiogenesis under FAK-I. To explore this, we treated HUVECs with FAK-I
for three days and assayed the lysates (Figure 22A-B). FAK-I reduced the expression of
several factors essential for angiogenesis including Vascular endothelial growth factor
(VEGF), basic FGF (bFGF), tissue inhibitor of metalloprotease-1 (TIMP-1), insulin-like
growth factor (IGF) binding protein 2 (IGFBP2) and heparin binding-epidermal growth
factor (HB-EGF) expression, however only HB-EGF displayed a consistent reduction in
protein and mRNA (Supplementary figure A5). HB-EGF is a member of the epidermal
growth factor (EGF) superfamily of ligands [145]. HB-EGF precursor is synthesized as a
transmembrane domain protein that when needed, gets cleavage by ADAMS matrix
metalloproteases (Supplementary figure A6) [146]. The soluble fragment of HB-EGF
acts as an autocrine and paracrine mitogen for various cell types including: smooth
muscle cells (SMCs), endothelial cells, pericytes, fibroblast, hepatocytes, among others
[147-151]. HB-EGF stimulation has been shown to be involved in an autocrine loop that
increases the expression of major regulators of angiogenesis such as VEGF [152]. Also,
the cytosolic fraction of HB-EGF has been shown to go to the nucleus where it can
promote the expression of genes important for proliferation and migration [153,154].
Out of the angiogenic factors reduced by FAK-I, we decided to explore the
mechanism by which nuclear FAK reduced HB-EGF (Figure 23A). FAK-I reduced HBEGF protein (Figure 23B) and mRNA (Figure 23C). We used MS1 for the next sets of
biochemical experiments. First, we validated that FAK-I could reduce HB-EGF protein
(Figure 24A), mRNA (Figure 24B) and proliferation of MS1 (Figure 24C). Since HBEGF is a growth factor and it has been shown before that FAK can be activated
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downstream of multiple transmembrane growth factor receptors (reviewed in chapter I),
to explore the impact of HB-EGF signaling in FAK activation, we cloned HB-EGF amino
acids 64-149 from HUVECs cDNA into a bacterial expression system, generating His
tagged HB-EGF64-149aa. HB-EGF expression was induced using IPTG in BL21 (DE3) and
pulled down His using single-step affinity chromatography with Ni-NTA matrix. We
separated purified proteins using electrophoresis in combination with acrylamide gel and
confirmed that the purified protein was the size expected (Supplementary figure A7). To
explore the impact of HB-EGF signaling in FAK activity we starved MS1 cells and
treated them with the purified recombinant HB-EGF (rHB-EGF) (Figure 25). rHB-EGF
treatment promoted FAK activation, shown by an increase in pY397 FAK (Figure 25B).
We also pulled down EGF receptor (ligand for HB-EGF) to confirm that rHB-EBF was
functional. EGR receptor is a tyrosine kinase receptor and we showed by
immunoprecipitation that our rHB-EGF promoted EGR receptor phosphorylation (Figure
25C).
Yes-associated protein (YAP) regulates HB-EGF transcription
To investigate the signaling mechanism that could potentially regulate FAKmediated HB-EGF expression in ECs we investigated previous literature pertaining to
HB-EGF transcription. Some reports suggested that the transcriptional co-activator YAP
could regulate HB-EGF expression in certain cell lines (Figure 26A) [155]. We wanted to
explore the impact of FAK inhibition in YAP protein expression in ECs. MS1 were
treated with FAK-I for 24 or 48 hours and the impactor of FAK-I in YAP was assessed
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Figure 21. FAK inhibition promotes nuclear FAK localization and reduces
proliferation in endothelial cells (ECs).
(A) Human Umbilical Vein Endothelial cells (HUVECs) cells were treated
with/without FAK-I (VS-6063, 2.5 μM) for 24 hours. Immunostaining for FAK (green)
cand pY397 FAK, active marker (red) or FAK and Dapi (blue) are shown. Merge:
Green, red, and DAPI (blue) bottom panels. (B) HUVECs were treated with FAK-I
(VS-6063, 2.5 μM) and cells were count at the indicated timepoints. (n=3, +/-SEM)
was measured by RT-qPCR. *** p<0.001. ** p<0.01 compared to vehicle.
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Figure 22. Nuclear FAK reduces multiple angiogenic factors in angiogenesis
array.
(A) Experimental timeline for treatment is shown. (B) Relative levels of 55
angiogenesis-related proteins presented as dotted duplicates measured by antibody
capture array from HUVECs in the presence or absence of FAK-I (VS-6063, 2.5 μM)
for 3 days. Proteins are ordered by alphabetical order. Reference Spots (A1, A2),
Activin A (A5, A6), ADAMTS-1 (A7, A8), Angiogenin (A9, A10), Angiopoietin-1
(A11, A12), Angiopoietin-2 (A13, A14), Angiostatin/Plasminogen (A15, A16),
Amphiregulin (A17, A18), Artemin (A19, A20), Reference Spots (A23, A24),
Coagulation Factor III (B1, B2), CXCL16 (B3, B4), DPPIV (B5, B6), EGF (B7, B8),
EG-VEGF (B9, B10), Endoglin (B11, B12), Endostatin/Collagen XVIII (B13, B14),
Endothelin-1 (B15, B16), FGF acidic (B17, B18), FGF basic (B19, B20), FGF-4 (B21,
B22), FGF-7 (B23, B24), GDNF (C1, C2), GM-CSF (C3, C4), HB-EGF (C5, C6),
HGF (C7, C8), IGFBP-1 (C9, C10), IGFBP-2 (C11, C12), IGFBP-3 (C13, C14), IL-1
(C15, C16), IL-8 (C17, C18), TGF-1 (C19, C20), Leptin (C21, C22), MCP-1 (C23,
C24), MIP-1 (D1, D2), MMP-8 (D3, D4), MMP-9 (D5, D6), NRG1-.1 (D7, D8),
Pentraxin 3 (D9, D10), PD-ECGF (D11, D12), PDGF-AA (D13, D14), PDGFAB/PDGF-BB (D15, D16), Persephin (D17, D18), Platelet Factor 4 (D19, D20), PlGF
(D21, D22), Prolactin (D23, D24), Serpin B5 (E1, E2), Serpin E1 (E3, E4), Serpin F1
(E5, E6), TIMP-1 (E7, E8), TIMP-4 (E9, E10), Thrombospondin-1 (E11, E12),
Thrombospondin-2 (E13, E14), uPA (E15, E16), Vasohibin (E17, E18), VEGF (E19,
E20), VEGF-C (E21, E22), Reference Spots (F1, F2), Negative Control (F23, F24).
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Figure 23. Nuclear FAK reduces heparin binding epidermal growth factor (HBEGF) expression.
(A) Optical densities of the top targets modulated by FAK-I in the angiogenesis array
are displayed as heatmap. (B) Left over of cleared lysates were analyzed by western
blotting and immunoblots for total FAK, pY397 FAK (active FAK) and HB-EGF are
shown. GAPDH and β-actin were used as loading control. (C) HUVECs cell were
treated with FAK-I (VS-6063, 2.5 μM) for 3 days. RNA was isolated and HB-EGF
mRNA was measured by RT-qPCR (n=3, +/-SEM). *** p<0.001 compared to vehicle.
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Figure 24. Nuclear FAK reduces HB-EGF expression in mouse endothelial cells
MS1.
(A) MS1 were treated with FAK-I (VS-6063, 2.5 μM) for the indicated timepoints and
immunoblots for total FAK, pY397 FAK (active FAK) and HB-EGF are shown.
GAPDH was used as loading control. (B) MS1 cell were treated with FAK-I (VS6063, 2.5 μM) for the indicated timepoints, RNA was isolated and HB-EGF mRNA
was measured by RT-qPCR (n=3, +/-SEM). (C) MS1 cells were treated with FAK-I
(VS-6063, 2.5 μM) and cells were count at the indicated time points (n=3, +/-SEM).
*** p<0.001. ** p<0.01 compared to vehicle.
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Figure 25. Recombinant HB-EGF activates FAK and promotes epidermal growth
factor receptor (EGFR) phosphorylation.
(A) Graphic timeline is shown. MS1 cell were starved for 16 hours and exposed to
recombinant HB-EGF (rHB-EGF) for 15mins (B) input lysates are shown (C) lysates
were immunoprecipitated with Epidermal growth factor receptor antibody and IP
proteins were probed with the indicates antibodies.
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Figure 26. The transcriptional co-activator YAP controls HB-EGF expression.
(A) Graphic summary of the transcriptional targets of YAP in cancer cells. (B) MS1
cells were treated with FAK-I (VS-6063, 2.5 μM) for the indicated timepoints and
immunoblots for total FAK, pY397 FAK (active FAK), HB-EGF, YAP are shown.
GAPDH was used as loading control. (C) MS1 cell were treated with FAK-I (VS6063, 2.5 μM) for the indicated timepoints. Cell were lysate and mRNA for YAP was
measured (n=3, +/-SEM). ns>0.05
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by western blot. FAK-I reduced YAP protein expression (Figure 26B) without changing
YAP transcript (Figure 26C).
FAK inhibition reduces YAP protein stability
To explore the nature of YAP and FAK relationship we performed
immunoprecipitation of FAK or IgG in MS1 in the presence or absence of FAK-I. First,
short time FAK-I treatment reduced YAP protein in the input lysate (Figure 27A).
Secondly, although, FAK and YAP interacted in the absence or presence of FAK
inhibitor, less YAP was observed to interact with FAK under FAK-I (Figure 27B). Some
previous literature showed using In vitro kinase assay that YAP is a substrate for FAK
[28]. YAP contains 6 tyrosine residues that could potentially get phosphorylated [156],
the tyrosine residue of YAP that gets phosphorylated by FAK has not been identified. To
explore global changes in YAP tyrosine phosphorylation MS1 were treated with FAK-I
and investigated the phosphorylation status of the tyrosine residue 407 of YAP which is
the most studied tyrosine phosphorylation of YAP. As observed before, FAK-I treatment
reduced total YAP protein. The phosphorylation of YAP tyrosine 407 was reduced by
FAK-I (Figure 28A). To assess potential changes in global phosphorylation of YAP we
performed phosphotyrosine immunoprecipitation and demonstrated that less tyrosine
phosphorylated YAP was pulled down in the presence of FAK-I (Figure 28B).
Since YAP is a nuclear protein and we already observed reduction in YAP
transcriptional target HB-EGF under FAK-I we wanted to explore the impact of YAP
tyrosine phosphorylation in YAP nuclear localization. MS1cells were treated with FAK-I
for several timepoints and tracked YAP protein and localization were tracked down by
western blot and immunofluorescence respectively. FAK-I not only progressively
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reduced YAP protein (Figure 29A) but loss of YAP tyrosine phosphorylation also
promoted YAP cytosolic sequestration (Figure 29B). Some groups have reported that
YAP cytosolic sequestration is important for YAP proteasomal degradation [157]. To
explore this possibility, we performed YAP immunoprecipitation in the presence or
absence of FAK-I and observed a marked increase in YAP ubiquitination under FAK-I.
We also used a proteasomal inhibitor MG-132 and noticed that FAK-I co-treatment with
MG-132 reduced FAK mediated reductio in YAP protein (Figure 30A-B). To draw the
connection between FAK-YAP and HB-EGF signaling axis we stably knockdown YAP
(shYAP) and observed reduction in HB-EGF transcript (Figure 31 A-B).
FAK inhibition reduces angiogenesis in vivo
To explore the impact of FAK-I in pathological angiogenesis in vivo we used an
angiogenic VEGF/FGF Matrigel plug. (Figure 32A). FAK-I reduced in vivo angiogenesis
(Figure 32B). Vehicle-treated mouse displayed strong recruitment of ECs to the plug;
however, FAK-I reduced ECs migration to the plug (Figure 32B, top panels).
Immunofluorescence of the ECs contained in the plugs (vWF positive cells) showed that
FAK-I treated plug migrated in a less organized matter compared to vehicle (Figure 32B,
bottom panels). We also quantified the number of EC contained in the plug by FITC
lectin and observed that less fluorescent was observed in the FAK-I treated plugs (Figure
32C). We also wanted to explore if FAK-I could regulate the abundance of FAK
subcellular localization and subsequent YAP transcriptional target HB-EGF in the
Matrigel plug. For this matter, we performed cryosection of Matrigel plugs of mice
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Figure 27. FAK inhibition reduces YAP protein stability.
MS1 cells were treated with FAK-I (VS-6063, 2.5 μM) for 6 hours (hrs). (A) Input
lysates from MS1 cells were probe with FAK, pY397 FAK (active FAK), HB-EGF,
YAP, pY407 YAP antibodies. β-actin was used as loading control. (B) Lysates were
immunoprecipitated with, anti-FAK or IgG. Eluted proteins were probed with total
FAK and YAP.
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Figure 28.FAK inhibition reduces YAP tyrosine phosphorylation.
MS1 cells were treated with FAK-I (VS-6063, 2.5 μM) for the indicated timepoints
(hrs). (A) Immunoblots were probe with the indicated antibodies (A) Input lysates from
MS1 cells were probe with FAK, pY397 FAK (active FAK), HB-EGF, YAP, pY407
YAP antibodies. β-actin was used as loading control. (B) Lysates were
immunoprecipitated with, anti-pTyrosine (pTyr) antibody. Eluted proteins were probed
with total pTyr and YAP.
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Figure 29. FAK inhibition reduces YAP nuclear localization.
MS1 cells were treated with FAK-I (VS-6063, 2.5 μM) for the indicated timepoints
(hrs). (A) Immunoblots for FAK, pY397 FAK (active FAK), HB-EGF, YAP, pY407
YAP are shown. β-actin was used as loading control. (B) MS1 cells were treated with
FAK-I for the indicated timepoints and immunofluorescence staining for YAP (green)
is shown.
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Figure 30. FAK inhibition increases YAP protein ubiquitination.
(A) MS1 were treated with FAK-I (VS-6063, 2.5 μM) only or in combination with
MG132 (20 μM) for 6 hrs. Immunoblots for FAK, pY397 FAK (active FAK), HBEGF, YAP, pY407 YAP are shown. β-actin was used as loading control. (B) Lysates
were immunoprecipitated with, YAP crosslinked antibodies. Eluted lysates were
probed for total FAK, YAP and Ubiquitin.
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Figure 31. Stable knockdown of YAP reduces HB-EGF expression in MS1.
MS1 were transduced lentivirus to stable knockdown (KD) YAP or scramble control
(shScr). After selection MS1 were lysate and mRNA of (A) YAP and (B) HB-EGF was
measured by RT-qPCR (n=3, +/-SEM). (C) MS1 YAP-KD cells were lysate and
probed with YAP and HB-EGF. GAPDH was used ass loading control. * p<0.05
compared to shScr.
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Figure 32. FAK inhibition reduced angiogenesis in vivo.
(A) Experimental timeline for Matrigel angiogenesis assay. (B) Brightfield picture
(top) of whole Matrigel plug at endpoint. Immunofluorescence of cryosection of the
Matrigel plugs (bottom) stained with vWF (Von Willebrand factor, an endothelial cell
marker) in green and nuclear stain DAPI, merge is shown. (C) Quantification of FITClectin signal from the Matrigel plug lysates at endpoint (n=3, +/-SEM). **p<0.01
compared to vehicle.
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Figure 33. FAK inhibition reduces HB-EGF expression in vivo.
Immunostaining of Matrigel plug cryosections stained with HB-EGF (green) and vWF,
endothelia cell marker (red) or FAK and Dapi (blue) are shown. Merge: Green, red,
and DAPI (blue) far right panel.
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Figure 34. FAK inhibition reduces YAP expression and nuclear localization in
vivo.
Immunostaining of Matrigel plug cryosections stained with YAP (green) and vWF,
endothelia cell marker (red) or FAK and Dapi (blue) are shown. Merge: Green, red,
and DAPI (blue) far right panel.
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Figure 35. FAK inhibition reduces HB-EGF mRNA in vivo.
(A) Experimental timeline for Matrigel angiogenesis assay. (B) Brightfield picture
(top) of whole Matrigel plug at endpoint. (C) RNA was extracted from Matrigel plugs
and RT-qPCR was performed to measure HB-EGF mRNA. (n=3, +/-SEM).
****p<0.0001 compared to vehicle.

88

Figure 36. Breeding strategy to generate EC-specific FAK kinase dead (KD)
mouse.
Floxed FAK mice containing two loxP sites flanking exon 3 of the FAK gene [136]
were crossed with End-SCL-Cre-ER(T) mice containing tamoxifen-inducible CreER(T) driven by the 5′ endothelial enhancer of the stem cell leukemia locus [158].At 6
week of age, littermates of FAK fl/fl ;Cre(+) and FAK fl/fl ;Cre(−) mice were treated
with 2 mg tamoxifen every 2 days for 2 weeks to generate “wild-type” (WT) mice
(tamoxifen-treated mice with no Cre expression and thus no FAK deletion) and
inducible EC–specific FAK knockout (“i-EC-FAK-KO”) mice (tamoxifen-induced
EC-specific Cre expression resulting in FAK deletion).
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Figure 37. Endothelial cell FAK activity is needed for angiogenesis.
(A) Experimental timeline for Matrigel angiogenesis assay. (B) Brightfield picture
(top) of whole Matrigel plug at endpoint in in mouse expressing catalytic inactive FAK
in endothelial cells. Immunofluorescence of cryosection of the Matrigel plugs (bottom)
stained with vWF (Von Willebrand factor, and endothelial cell marker) in green and
nuclear stain DAPI, merge is shown. (C) Quantification of FITC-lectin signal
contained at endpoint.
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Figure 38. FAK inhibition reduces HB-EGF expression and proliferation of
hemangioma.
(A) Representative western blot of primary endothelial cell extracted from vascular
tumor (hemangioma) treated with FAK-I (VS-6063, 2.5 μM) for the indicated
timepoints and probed using the indicated antibodies. Hemangioma cells were treated
with FAK-I (VS-6063, 2.5 μM) mRNA was isolated and HB-EGF (B) and YAP (C)
mRNA was measured by RT-qPCR at the indicated timepoints (n=3, +/-SEM). (D)
Hemangioma cells were treated with FAK-I (VS-6063, 2.5 μM) cells were the
indicated timepoints (n=5, +/-SEM). ns p>0.05 **p<0.01 ***p<0.001 compared to
vehicle.
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treated with vehicle or FAK-I and observed that FAK-I treated groups compared to the
vehicle displayed: reduced HB-EGF (Figure 33) and reduced YAP which was mostly
localized to the cytosol (Figure 34) in all cells within the plug. We also looked at the
protein and localization of vWF positive cells specifically (supplemental figureA8-A9).
We also isolated mRNA from the Matrigel plug and interrogated HB-EGF transcript by
RT-qPCR. Like in our vitro data sets, FAK-I reduced HB-EGF mRNA in the plug
(Figure 35A-B). Since FAK-I blocks FAK activity in all cells within the Matrigel plug
and whole experimental subject, we wanted to explore the impact of FAK nuclear
localization specifically in ECs and how this affects EC migration and response to an
angiogenic stimulus. To test this, we used an EC specific kinase-inactive mouse (Figure
36). Similarly, to what we observed before, nuclear localized-FAK reduced ECs
migration to the Matrigel plugs (Figure 37B-C).
FAK inhibition blocks hemangioma proliferation
To explore the significance of FAK signaling and localization in vascular tumors,
called hemangioma, I treated infantile hemangioma cells with FAK-I (inhibitor titration
in Supplemental figure A10) and looked at changes in HB-EGF and YAP protein (Figure
38A), mRNA (Figure 38B-C) and proliferation (Figure 38D). Overall FAK-I blocked
HB-EGF expression and reduced pY407 YAP while no change in YAP mRNA was
observed. Since we noticed that FAK-I blocked proliferation, on other ECs we wanted to
explore if we could replicate this in primary hemangioma cells. Similarly, FAK-I reduced
hemangioma proliferation (Figure 38D). We wanted to investigate the expression pattern
of FAK in vascular tumors. For this hemangioma tumor sections were analyzed by
immunofluorescence, using normal skin vWF positive cells as control, with FAK, active
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FAK and YAP in combination with EC marker, vWF, to determine the expression
patterns of these proteins in vascular tumors. In accordance with our previous results,
vWF positive cells displayed abundant cytosolic localized FAK (Figure 39) and high
active FAK marker pY397 FAK (Figure 40). Like Matrigel angiogenesis model,
hemangioma tumors also displayed abundant YAP nuclear-localized, but very low YAP
was detected in vessels from normal skin (Figure 41).

Discussion
In this chapter, I wanted to explore the impact of FAK activity and localization in
the regulation of ECs pathological behaviors. For this, we used pharmacological FAK
inhibitors (FAK-I) and explored the impact of these in EC proliferation using in vivo and
in vitro assays. First, FAK-I promoted FAK nuclear localization in ECs and this nuclear
localized-FAK was associated with reduced EC proliferation. To rule out the possibility
that this reduction in cell proliferation was due to a spike in EC-death due to the toxicity
of the inhibitor, we titrated FAK-I in ECs (Supplementary figure A4). FAK-I displayed a
certain degree of toxicity and an increase in FAK-I concentration increases cell death, we
choose that concentration that was enough to block FAK activation (pY397 FAK mark)
and displayed minimal apoptotic cells (assessed by PI staining). This reduction in
proliferation was probably because FAK-I (nuclear-localized FAK) reduced the
expression of multiple factors that are key in promoting angiogenesis such as VEGF,
FGF and HB-EGF in the angiogenesis array. We used the RT-qPCR approach to evaluate
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Figure 39. FAK localized to the nucleus in endothelial cells of the normal skin but in hemangioma
lesions is localized to the cytosol.
Immunostaining of normal skin (top) or hemangioma tumor (bottom) cryosections stained with FAK (green)
and vWF, endothelia cell marker (red) or FAK and DAPI (blue) are shown. Merge: Green, red, and DAPI
(blue) far right panel.
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Figure 40. FAK is highly active in hemangioma tumors.
Immunostaining of normal skin (top) or hemangioma tumor (bottom) cryosections stained with pY397
FAK, active FAK marker (green) and vWF, endothelia cell marker (red) or FAK and DAPI (blue) are
shown. Merge: Green, red, and DAPI (blue) far right panel.
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Figure 41. YAP expression in hemangioma.
Immunostaining of normal skin (top) or hemangioma tumor (bottom) cryosections stained with YAP
(green) and vWF, endothelia cell marker (red) and DAPI (blue) are shown. Merge: Green, red, and DAPI
(blue) far right panel.

changes in mRNA in these factors. We observed that nuclear FAK reduced HB-EGF
mRNA and protein in various ECs while no impact in HB-EGF mRNA was observed in
non-ECs cell line such as mSMCs (Supplemental figure A11). This suggests that FAKregulation of HB-EGF might be a cell-specific mechanism.
We explore the transcriptional network that may regulate HB-EGF mRNA
synthesis in EC and discovered that the transcriptional co-activator YAP [155], was a
potential candidate. FAK-I reduced YAP protein stability, potentially to the loss of YAP
tyrosine phosphorylation. The loss of YAP tyrosine phosphorylation led to an increase in
cytosolic retention of YAP. It’s been reported before that YAP phosphorylation played a
key role in regulated YAP protein turnover. We showed that FAK-I not only increased
YAP cytosolic retention but, also enhanced YAP ubiquitination. Overall suggesting that
FAK subcellular localization is important for YAP protein stability. Some previous
reports suggest that Yap could regulate transcription of FGF [159] as well but we didn’t
see significant changes in FGF mRNA under FAK-I (Supplementary figure A5). Also,
our data suggest that FAK might be responsible for the phosphorylation of YAP tyrosine
407. Moreover, the experimental approaches detailers in this chapter suggest that FAK
tightly regulates YAP transcriptional signaling by regulating various stages of YAP
protein modification such as: tyrosine phosphorylation and ubiquitination of YAP.
For the first time, the impact of FAK expression was studied in vascular tumors.
YAP-HB-EGF signaling axis in pathological angiogenesis samples using cryosection
form hemangioma tumors and observed that in normal skin vessel vWF positive cell
display strong nuclear-localized FAK and very. Low FAK activity, but lesion samples
FAK is strongly localized to the cytosol and displayed abundant pY397 FAK signal.
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FAK-I also blocked HB-EGF transcription in hemangioma primary cells and reduced
YAP protein. In addition to hemangioma, pathological angiogenesis represents a major
challenge in pathologies such as blinding eye diseases corneal neovascularization,
proliferative diabetic retinopathy, and age-related macular degeneration [160,161]. We
wanted to expel if FAK-I could prevent or block angiogenesis using a Matrigel in vivo
angiogenesis assay. FAK-I blocked angiogenesis and reduced HB-EGF transcription and
nuclear YAP localization.
Here we identified a novel signaling axis that regulates EC response to angiogenic
stimulus (Figure 42). FAK-I promoted nuclear FAK localization, and this reduced HBEGF transcription. YAP tyrosine phosphorylation controls HB-EGF transcription,
pharmacological inhibition of FAK reduced YAP tyrosine phosphorylation and reduced
YAP protein. The finding explored in this chapter shed light into a new way of
interpreting FAK subcellular localization in different pathologies. Inactive FAK retains
scaffold function that can influence multiple steps of pathology progression. There
remains a certain unanswered question, pertaining to the subcellular compartment where
YAP-FAK interact with or the role of FAK in YAP protein ubiquitination. Pathologies
such as hemangiomas have very limited treatment options for lesions that can’t be
excised by surgery. Since FAK inhibitors are undergoing clinical trials to treat cancer,
these results suggest that FAK inhibitors could also prove beneficial in blocking EC
proliferation associated with hemangioma.
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Figure 42. Model: FAK regulates HB-EGF transcription.
Downstream of growth factor receptors FAK gets activated and phosphorylated which
promotes FAK cytosolic signaling. In the cytosol compartment FAK can associate with
YAP and promote its tyrosine phosphorylation. Once tyrosine phosphorylated YAP
translocate to the nucleus where it can promote the transcription of HB-EGF. Under
FAK inhibition, FAK translocate to the nucleus where it can facilitate ubiquitination of
YAP.
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CHAPTER IV:
CONCLUSION

The impact of FAK catalytic function downstream of growth factor receptors and
integrins have been long appreciated, intervening with these signaling cascades by the
implementation of FAK inhibitors have proven beneficial to eradicate tumor growth
(reviewed in chapter I). We have demonstrated that catalytic inactivation of FAK,
promotes FAK nuclear localization and once in the nucleus FAK retains key kinase
independent functions that can impact several stages of gene expression, primordially by
regulating post-translational modification of nuclear proteins (reviewed in chapter I).
Despite the notorious roles of inactive FAK in the nucleus, the overall impact of this
remains to be explored. Exploring this aspect of FAK would help us to understand the
biology of pharmacological inhibitors of FAK (FAK-I) and potentially amplify their use.

Generation of mouse model to study the impact of FAK nuclear signaling
FAK knockout (KO) embryos display embryonic lethality due to mesodermal
growth arrest subsequent In vitro studies showed this was due to a p53- and p21-mediated
cell proliferation defects [11]. The study first found that FAK goes to the nucleus where it
promotes p53 ubiquitination and degradation to enhance cell proliferation. Detailed
examination of FAK amino acid sequences, led to the discovery of a set of mutations that
impaired FAK’s ability to go to the nucleus. The consecutive mutation of R177A
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(arginine to alanine) and R178A mutation resulted in profound nuclear localization defect
(Supplemental figure A12a-b). Although this work sets the bar for new ways of looking
at FAK signaling and open the door to previously unrecognized functions of FAK in the
nucleus, the understanding of nuclear FAK localization in mouse has not been
extensively explored. This was partially due to the lack of a mouse model that would
allow the manipulation of FAK subcellular localization. At the beginning of my work in
Dr. Steve Lim research group, I aim to characterize the importance of nuclear FAK
signaling during embryonic development. We generated genetic FAK Cyto mutation in
mouse to study the impact of FAK cyto-nuclear shuttling during embryonic development.
The FAK Cyto mutation was engineered using FLEx technology (Supplemental
figure A12c-e).This allows for the conditional turn on/off of genes of interest merely by
flipping and excising DNA sequences based on the orientation of the lox sites within the
transgene [162]. Our transgene sustains the expression of FAK WT in the absence of Cre
recombinase, but FAK Cyto mutation can be turned on permanently by Cre recombinase.
FAK Cyto was expressed from the FAK CytoFLEx cassette using a Cre recombinase
driven by the human beta gene promoter (β-actin Cre). I sat heterozygous breeding cages
FAK WT/Cyto on β-actin Cre background mouse. From tail DNA genotyping PCR, I was
able to detect all three possible genotypes FAK WT/WT, FAK WT/Cyto and FAK
Cyto/Cyto, in the presence of β-actin Cre, which suggest that this mutation doesn’t lead
to embryonic lethality like other FAK genetic mouse (FAK KO and FAK KD). This
could be because during the early stages of embryonic development a loss of activecytosolic FAK is needed to drive migration and proliferation of MEFs.
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Nuclear FAK fails to respond to epidermal growth factor (EGF) stimulation
Looking at the in vivo data presented in Chapter II and III under homeostasis
FAK is nuclear-localized. We aimed to design experiments to understand the impact of
this. I used site-directed mutagenesis to mutate FAK nuclear export signal (NES), to
generate a FAK mutant restricted to the nucleus potentially preserving its catalytic
function (Supplemental figure A13a). First, we did subcellular fractionation and noticed
this mutation enriched nuclear FAK (Supplemental figure A13b). To test if this nuclear
localized FAK could be activated by exogenous growth factor stimulation we transiently
expressed FAK WT (FAK construct that can freely shuttle between nucleus and cytosol)
and FAK Nuc (nuclear-restricted construct) and exposed cells to EGF (Supplemental
figure A13c). Interestingly FAK Nuc mutation failed to display active FAK marker
(pY397 FAK) compared to FAK WT (Supplemental figure A13d) in whole cell lysate
and in the immunoprecipitated FAK-HA (Supplemental figure A13e). Although more
characterization of the FAK- Nuc is needed, these results might suggest that in vivo the
cells in our body sent FAK to the nucleus to prevent FAK from being activated by
extracellular stimulus.

Nuclear FAK is an epigenetic regulator of tumor suppressor gene expression
In chapter II, we strived to explore the impact of epigenetics of nuclear FAK-I.
This project started as an expansion of our knowledge in SMCs, where FAK regulates the
transcriptional landscape of smooth muscle cells (SMCs) by regulating DNA
methyltransferase 3A (DNMT3A) protein stability. DNMT3A is a member of the DNA
methyltransferase family, on the contrary to the other members of the family which
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oversee maintain DNA methylation during replication, DNMT3A can regulate the
methylation of genes de novo. This is important because it can methylate genes based on
the cellular context of the cells. Looking at cancer cells alone, DNMT3A has been long
appreciated for silencing tumor suppressor genes [163], thus promoting uncontrolled
proliferation of cells. The reduction in global DNA methylation as a result of FAK-I
increased the expression of Suppressor of Cytokine Signaling 3 (SOCS3). The inducible
expression of SOCS3 reduced proliferation and viability. We showed that FAK-I
increased the SOCS3 expression in vivo. This data overall suggested nuclear FAK
prevented melanoma growth by increasing SOCS3 expression.
I was curious about the clinical relevance of this discovery and look up the
expression of DNM3A (although this is only looking at mRNA expression, not protein
like it was revised in Chapter II) and SOCS3 in melanoma and of these relate to patient
survival in data set from the TCGA (Supplemental figure A3a-b). Although neither
DNMT3A or SOCS3 are not considered prognosis markers for melanoma, it seems to be
a positive correlation between low DNMT3A and high SOCS3expression and better
survival chances.
Nuclear FAK appears to be a key regulator of tumor growth by regulating master
enzymes in DNA methylation. Retention of FAK cytosolic function allows B16F10 cells
to proliferate uncontrolled. Redistribution of FAK signaling to the nucleus efficiently
intervene with tumor growth demonstrating that FAK inhibitor efficiently blocks cell
growth by highlighting FAK nuclear function. This work opens a new paradigm of how
FAK pharmacological inhibitors work.
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Nuclear FAK reduced the expression of angiogenetic factor HB-EGF
In Chapter III, we aimed to understand the impact of FAK localization in
pathological angiogenesis. First FAK-I prompted FAK nuclear localization because and
blocked the proliferation of endothelial cells, we wondered if nuclear FAK was
responsible to block the expression of factors that promote endothelial cell proliferation.
For this, we used an angiogenesis array and observed that FAK inhibition reduced protein
of major angiogenic factors such as VEGF, FGF, EGF and HB-EGF. We wanted to focus
on the impact of FAK subcellular localization in the transcription of these genes. Nuclear
inactive FAK blocked HB-EGF transcription by reducing the protein stability of the
transcriptional coactivator YAP. We found that FAK inactivation reduced YAP tyrosine
phosphorylation, increases YAP ubiquitination, and promotes YAP cytosolic retention.
The deprivation of nuclear YAP signaling reduced its ability to promote HB-EGF
expression. We explored the impact FAK-YAP-HB-EGF signaling axis in vivo using
Matrigel angiogenesis assay and found that FAK-I: prompted nuclear FAK localization in
cells in the Matrigel. Similarly, FAK-I blocked HB-EGF expression and blocked nuclear
YAP localization. In the case of a vascular tumor, hemangioma, FAK-I blocked HB-EGF
proliferation and reduced YAP expression. In cryosection of hemangioma vascular
tumors, we observed that vWF positive cells displayed a strong pY397 FAK marker and
that FAK is abundantly expressed and localized to the cytosol.
I wanted to check the impact of FAK subcellular localization in HB-EGF mRNA.
For this, I isolated mRNA from HUVECS cells over-expression different mouse GFPFAK constructs (Supplemental figure A14). Each of these constructs exhibits differential
FAK subcellular localization WT (FAK that shuttles between nucleus and cytosol), KD
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(kinase-inactive, localized to the nucleus) and Cyto (cytosolic restricted FAK). Similarly
with the pharmacological inactivation data, nuclear inactive FAK displayed the least HBEGF mRNA while FAK Cyto and WT displayed the most abundant HB-EGF mRNA.
This is very preliminary data and further experimentations are needed to fully conclude
this.
Taken together, the data presented in this dissertation highlights the function of
FAK subcellular localization in tumor progression. In the context of tumor cells, these
use FAK cytosolic signaling to cytosolic targets that increase cell proliferation and
migration. FAK activation also excludes FAK from the nuclear compartment and keep
FAK away from regulating the protein stability of DNM3A, thus promoting the silencing
of tumor suppressors. This situates FAK as a master regulator of epigenetic in melanoma
cells. Similarly, endothelial cells use FAK subcellular localization to regulate the protein
stability of YAP and important transcriptional co-activator in charge of HB-EGF
expression.
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APPENDICES

Appendix A: Supplementary Figures

Figure A 1. Cartoon displaying the various layer of the epidermis.
Epidermis is the outer layer of the skin and is composed of cells that are
constantly undergoing cell division to replace the layer of skin that we shed daily.
The role of the epidermis is to act as our first barrier against foreign pathogens.
The epidermis is composed of squamous cells (the upper (outer) part of the
epidermis, which are constantly shed as new ones are formed-these cell can give
rise to squamous cell skin cancer), basal cells (lower part of the epidermis,
constantly divide to form new cells to replace the squamous cells that wear off
the skin’s surface-give rise to basal cell carcinomas) and melanocytes (pigment
generating cells- give rise to cutaneous melanoma).
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Figure A 2. Testing the impact of Tetracycline in B16F10 melanoma proliferation
and viability.
B16F10 stably expressing Tetracycline inducible empty vectors were treated with or
without Doxycycline (Doxy 1 μg/mL) for the indicated time points. (a) Cells were
lysate and mRNA levels of SOCS3 were measured by RT-qPCR at the indicated time
points (n=3, +/-SEM). (b) B16F10 cells expressing Tet-O empty vector were seeded in
the presence or absence of Doxy (1μg/mL) for the indicated timepoints (n=3, +/-SEM).
Cell counts are shown at the indicated timepoints. (c) B16F10 cells were treated with
Doxy (1μg/mL) for 24 hours and cell viability was evaluated by resazurin oxidation
(n=3, +/-SEM). ns p>0.05 compared to vehicle.
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Figure A 3. High DNMT3A and low SOCS3 expression associated with shorten
patient survival.
Kaplan-Meier plots summarize results from analysis of correlation between mRNA
expression level and survival of cutaneous melanoma patient based on (a)
DNMT3A and (b) SOCS3. Patients were divided based on level of expression into
one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows
time for survival (years) and y-axis shows the probability of survival, where 1.0
corresponds to 100 percent. Patients that are alive at last time for follow-up are
shown in blue and patients who have died during the study are shown in red. Data
obtained from the TCGA.
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Figure A 4. Titration of FAK inhibitor in HUVECs cells.
(a) HUVECs were treated with FAK-I for the indicated times and concentrations (µM).
Cells lysates were probed for pY397 FAK (active FAK) and GAPDH was used as
loading control. (b) HUVECs treated with FAK-I for 24 hrs were stained with
Propidium iodine (1 μg/mL, PI). PI is a fluorescence dye that in not permeable to
viable cells. Immunofluorescence for Hoechst (nuclear stanning, blue), PI (red) and
merge are shown.
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Figure A 5. Screening for FAK mediated changes in mRNA of angiogenic factor from the array
angiogenesis array.
HUVECs cell were treated with FAK-I (VS-6063, 2.5 μM) for 3 days. RNA was isolated and mRNA of the
indicated targets was measured by RT-qPCR (n=3, +/-SEM). *p<0.05 **p<0.01 compared to vehicle.

Figure A 6. HB-EGF signaling.
HB-EGF is synthetized and inserted in the plasma membrane as proHB-EGF. Upon
stimulation ADAM-mediated cleavage of proHB-EGF, results in the ectodomain
shedding of its N-terminal fragment (extracellular compartment, soluble Hb-EGF) and
generation of an intracellular C-terminal fragment (CTF). The soluble HB-EGF binds
to the EGFR and induces a rapid transient phosphorylation of EGFR. This
phosphorylation results in the transcription of various genes. Meanwhile the HB-EGFCTF is translocated into the nucleus, where it subsequently induces the nuclear export
of PLZF, Bcl6 and BAG-1, which function as transcriptional repressor of genes
important for cell cycle progression such as Cyclin A and Cyclin D2. Exclusion of
these nuclear proteins from the nucleus allows the progression of cell cycle.
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Figure A 7. Generation of recombinant HB-EGF (rHB-EGF).
(a) HB-EGF is synthetized as a pro-HB-EGF. This full form gets inserted into the
plasma membrane of the cells until needed. When needed ADAMs proteases oversee
cleaving HB-EGF. This process generates two fragments of the HB-EGF protein. First,
a soluble fraction with get release to the extracellular space and acts a paracrine or
autocrine mitogen. Secondly, the C-terminal portion of Hb-EGF can translocate to the
nucleus where it can influence nuclear transcriptional complex to promote cell growth.
We used primers to amplify the soluble fraction from HUVECs cDNA and expressed
and purified in bacteria. (b) Coomassie of the elution of the rHB-EGF. (c) Immunoblot
of rHB-EGF showing it contains His-tag.
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Figure A 8. FAK inhibition promotes nuclear FAK localization in vivo in Matrigel
plug.
Immunostaining of Matrigel plug cryosections stained with FAK (green) and vWF,
endothelia cell marker (red) or FAK and Dapi (blue) are shown. Merge: Green, red,
and DAPI (blue) far right panel.
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Figure A 9. FAK inhibition reduces active FAK marker in Matrigel plug.
Immunostaining of Matrigel plug cryosections stained with pY397 FAK (green) and
vWF, endothelia cell marker (red) or FAK and Dapi (blue) are shown. Merge: Green,
red, and DAPI (blue) far right panel.
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Figure A 10. Titration of FAK inhibitor in hemangioma cells.
Infantile hemangioma cells were treated with FAK-I (VS-6063) for 1 hour (hrs) with
the indicated concentrations. Cells lysates were probed for total FAK, pY397 FAK
(active FAK) and β-actin was used as loading control.
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Figure A 11. Impact of FAK inhibitor in HB-EGF expression in various cell lines.
Human endothelial cells lines (HUVECs and human aortic endothelial cells, HAoECs),
mouse endothelial cells (isolated from pancreatic islets, MS1 and isolated from lung,
mECs) and mouse smooth muscle cells (mSMCs) were treated with FAK-I (VS-6063,
2.5 μM) for 3 days. Cell were lysate and mRNA of HB-EGF was measured by RTqPCR (n=3, +/-SEM). ns p>0.05 *p<0.05 ***p<0.001 compared to vehicle.
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Figure A 12. Generation of FAK Cyto mouse.
(a) Localization is determinate by of clusters of basic residues (blue) and acidic
residues (red) on the surface of the FAK FERM domain visualized using MacPyMOL.
(b) Live cell imaging was used to follow GFP-FAK WT (FAK Wt) and GFP-FAK
R177A, R178A (FAK Cyto) distribution upon leptomycin B; LepB (10 ng/ml) or
ethanol (vehicle) addition for 4 hr. Scale bar, 10 μm. (Figure adapted from Lim S.T., et
al, Molecular Cell 2008). (c) Flip excision switch (FLEx) FAK Cyto construct. In the
absence of Cre recombinase this construct allows the expression of FAK Wt. (d) In the
presence of Cre recombinase, DNA sequences flanked by lox sites in opposites
orientation will be flipped, changing the orientation of FAK Cyto minigene (red
rectangle) from anti to sense orientation. (e) The third recombination cycle excises
wildtype exon 6 and 7 (green rectangles) and FAK Cyto minigene remains in FAK
allele.
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Lep B (4hr)

Figure A 13. Nuclear localized FAK failed to be activated by growth factor
signaling.
(a) We used site directed mutagenesis to mutate of four of leucine (L) to alanine (A)
L518A/L520A/L523A/L525A (nuclear localization sequence also referred as NES)
that were previously identified to be responsible for FAK nuclear exit (Nuc FAK). (b)
HA-tagged FAK constructs: WT: wildtype FAK that freely shuttles between nucleus
and cytosol, Cyto: Cytosolic restricted FAK mutant and Nuc: NES mutant was
transiently over expressed in HEK 293T cells and subcellular fractionation was
performed. C: cytosolic fraction N: nuclear fraction. (c) Experimental timeline for
immunoprecipitation experiment. (d) Lysates of HEK 293T transiently expressing WT:
Wildtype-HA FAK Nuclear (Nuc): NES mutant were starved and treated with EGF
20ng/mL for 15min. (e) Immunoprecipitation of HA FAK. Immunoprecipitated lysates
were probed with HA and active FAK.
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Figure A 14. Nuclear FAK-localized construct reduced HB-EGF transcription.
HUVECs cell were transduced GFP (empty vector, EV), GFP-FAK wildtype (WT,
FAK construct that can shuttle between nucleus and cytosol), kinase dead (KD,
catalytic inactive FAK which is nuclear enriched) and Cyto restricted FAK (Cyto, FAK
construct in which FAK nuclear localization sequence has been disrupted). Cells were
lysate and mRNA were isolated. HB-EGF mRNA was measured.
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Appendix B: Supplementary Table
Table A1: Targets of the angiogenesis array and their impact in angiogenesis
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Target/Control

Gene
ID

Alternate
Nomenclature

Activin A

3624

ADAMTS-1

9510

Angiogenin

283

ANG

Angiopoietin-1

284

Ang-1

Angiopoietin-2

285

Ang-2

Angiostatin/Plasminogen

5340

Amphiregulin
Artemin
Coagulation Factor III

374
9048
2152

Role in angiogenesis
Blocks angiogenesis by inhibiting
endothelial cell proliferation.
Reduce angiogenesis by sequestering
angiogenic factor.
Promotes angiogenesis by stimulating
endothelial cell proliferation.
Important promotes embryonic angiogenesis
but when uncontrolled can lead to vessel
destabilization
Binds surface receptor in endothelial cells
and regulates endothelial cell responsiveness
based on the cellular context
Regulates angiogenesis by facilizing
endothelial cell migration through
extracellular matrix.

AR
TF

Safeguards the vascular integrity of tissues
by initiating the coagulation cascade
following vessel injury.

Reference
[164]
[165,166]
[167]
[168]
[169]
[170]
[171]
[172]
[172]

Table A1 cont.
Alternate
Nomenclature
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Target/Control

Gene ID

CXCL16

58191

DPPIV

1803

EGF

1950

EG-VEGF

84432

PK1

Endoglin

2022

CD105

Endostatin/Collagen XVIII

80781

Endothelin-1

1906

ET-1

FGF acidic

2246

FGF-1

FGF basic

2247

FGF2

FGF-4

2249

CD26

Role in angiogenesis
Promotes endothelial cell migration,
proliferation, and tube formation.
Blocks angiogenesis by promoting
degradation of angiogenic growth
factors.
Promotes endothelial cell migration,
proliferation, and tube formation.
Promotes growth of endocrine gland
endothelium.
Context depended on function,
expressed by proliferating endothelial
cells but can promote endothelial cell
dysfunction.
Blocks angiogenesis by blocking
VEGFR-2.
Mitogen for vascular cells, especially
endothelial cells.
Stimulate endothelial cell
proliferation and the physical
organization of endothelial cells into
tube-like structures.
Stimulate endothelial cell
proliferation and the physical
organization of endothelial cells into
tube-like structures.
Promotes endothelial cell migration,
proliferation, tube formation and
VEGF-A upregulation.

Reference
[173]
[174]
[175]
[176]
[177]
[178]
[179]
[180]

[181]

[182]

Table A1 cont.
Target/Control

Gene ID

Alternate
Nomenclature
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FGF-7

2252

KGF

GDNF

2668

GM-CSF

1437

HB-EGF

1839

HGF

3082

IGFBP-1

3484

IGFBP-2

3485

IGFBP-3

3486

IL-1β

3553

IL-1F2

IL-8

3576

CXCL8

LAP (TGF-β1)

7040

Leptin

3952

Role in angiogenesis
Promotes endothelial cell migration,
proliferation, tube formation and
VEGF-A upregulation.
Promoted migration and endothelial
tube formation.
Promotes angiogenesis by enhancing
endothelial cell function.
Promotes vascular cells proliferation
and migration.
Vascular mitogen that stimulates cell
migration and tubular morphogenesis.
Promotes endothelial cell migration
and proliferation.
Promotes endothelial cell migration
and proliferation.
Promotes endothelial cell migration
and proliferation.
Promotes proliferation and migration
of endothelial cells.
Promotes angiogenesis by increasing
VEGF expression.
Usually associated with endothelia
cell proliferation, however TGF-β
signaling can have angiogenic and
angiostatic properties, depending on
expression levels and the tissue
context.

Reference
[183]
[184]
[185]
[186-189]
[190]
[191]
[192]
[193]
[194]
[195]

[196]

[197]

Table A1 cont.
Alternate
Nomenclature
CCL2
CCL3
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Target/Control

Gene ID

MCP-1
MIP-1α
MMP-8
MMP-9

6347
6348
4317
4318

NRG1-β1

3084

HRG1-β1

Pentraxin 3 (PTX3)

5806

TSG-14

PD-ECGF
PDGF-AA
PDGF-AB/PDGF-BB

1890
5154
5155

Persephin

5623

Platelet Factor 4 (PF4)
PlGF
Prolactin
Serpin B5
Serpin E1
Serpin F1
TIMP-1
TIMP-4
Thrombospondin-1
Thrombospondin-2

5196
5228
5617
5268
5054
5176
7076
7079
7057
7058

Role in angiogenesis
Promotes proliferation and migration.
Promotes proliferation and migration.
Promotes endothelial cell migration.
Reduced in vivo angiogenesis.
Type of erbB receptor, promotes
endothelial cell proliferation.
Promotes proliferation and migration
of endothelial cells.
Stimulates the DNA synthesis and
chemotaxis of endothelial cells in
vitro and angiogenesis in vivo.

CXCL4

Studies in cancer cells, where it
promoted cell proliferation.
Inhibitor of angiogenesis.
Endothelial cell mitogen.
Endothelia cell growth factor

Maspin
PAI-1
PEDF

Role in angiogenesis seems to be
context depend.
These act as inhibitors of MMPs.
Negative regulator of angiogenesis.

TSP-1
TSP-2

Potent angiogenesis inhibitor.

Reference
[198]
[199]
[200]
[201]
[202]
[194]
[203-205]
[206]
[207]
[208]
[209]
[210]

[211,212]
[213]

Table A1 cont.
Target/Control

Gene ID

uPA

5328

Alternate
Nomenclature

Role in angiogenesis

Reference

Promotes endothelia cell proliferation

[214]
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